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1. INTRODUCTION 
The goal of any drug delivery system is to provide a therapeutic amount of 
drug to a proper site in the body in order to promptly achieve and thereby maintain the 
desired drug concentration. The drug delivery system should deliver the drug at a rate 
dictated by the needs of the body over a period of treatment
1
. 
The best new therapeutic entity in the world is of little value without an 
appropriate delivery system. Tablet delivery system can range from simple immediate 
release formulations to complex extended or modified release dosage forms. The most 
important role of drug delivery system is to get the drug delivered to the site of action 
in sufficient amount & at the appropriate rate. However it should meet other important 
criteria such as physical & chemical stability, ability to be mass-produced in a manner 
that assures content uniformity. 
Solid dosage forms are widely prevalent due to their age-old application.  
Especially, oral solid formulations hold a high potential as they serve to be most 
convenient for the administration of drugs.  More than 50% of drug delivery systems 
available in the market are oral drug delivery systems. They offer convenience and 
ease of administration, greater flexibility in dosage form design and ease of 
production and low cost.  Pharmaceutical oral solid dosage forms have been used 
widely for decades mainly due to their convenience of administration and their 
suitability for delivery of drugs for systemic effects.  The most commonly used 
pharmaceutical solid dosage forms today include granules, pellets, tablets and 
capsules. 
1.1 MULTILAYERED TABLETS
8
: 
When two or more active pharmaceutical ingredients are needed to be 
administered simultaneously and they are incompatible, the best option for the 
formulation pharmacist would be to formulate multilayered tablet. It consists of 
several different granulations that are compressed to form a single tablet composed of 
two or more layers and usually each layer is of different colour to produce a 
distinctive looking tablet. Each layer is fed from separate feed frame with individual 
weight control. Dust extraction is essential during compression to 
avoidcontamination. Therefore, each layer undergoes light compression as each 
component is laid down. This avoids granules intermixing if the machine vibrates. 
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1.2 BILAYER TABLETS
9
: 
Bilayer tablet is a unit compressed tablet dosage form intended for oral 
administration. It comprises of two layers in which one layer is formulated as a 
conventional or immediate release part and another layer as modified release part or 
both of the former or later of the same or different drugs.Bilayer tablets enjoys the 
benefit of combining two drug with modified release pattern and scores over other 
formulations in terms of ease of manufacture, scale- up feasibility that caters the 
demands of industries. Unlike conventional formulations, there is a lack of saw tooth 
kinetics ensuring effective therapy with better plasma drug level.
2,3.
 
1.2.1  RATIONALE OF THE FORMULATION
9
: 
The basic rational is to alter the pharmacokinetics and pharmacodynamic of 
the pharmacologically active moieties by using innovative drug delivery system or by 
modifying the molecular structure or by physiological parameters inherent in the 
selected route of administration. 
 Where the two different drugs of same pharmacological category or dissimilar 
category are found to be incompatible.
4,5,6,7.
 
 Where there is a therapeutic intention to formulate one layer as a immediate 
release layer and the other one as modified layer
3,4
. 
 Where we need the follow up therapy of one drug being released followed by the 
other drug in an sequential manner
4
. 
Based on the therapeutic intention to tackle the complicated disorder with 
multiple symptoms or monotherapy or adjuvant therapy , many layers are formulated  
belonging to similar pharmacological category of drug or dissimilar pharmacological 
category of drugs with altered biopharmaceutical parameters ranging from both the 
layers. 
 
 
 
 
 
 
 
Chapter-1                                                                                                    Introduction 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  3 
 
Advantages of bilayer tablet
2,3
:
 
1. Incompatible substances can be separated by formulating them in separate 
layers as two layered tablets. 
2. Bilayer tablets require fewer materials when compared to the compression 
coated tablets. 
3. The weight of each layer can be accurately controlled in contrast to putting 
one drug of a combination product in sugar coating. 
4. Bilayer tablets have enabled the development of controlled delivery of active 
pharmaceutical ingredients with predetermined release profiles. 
5. Different release profiles of the drugs can be achieved by combining layers of 
drugs with various release patterns or by combining slow release with 
immediate release layers. 
6. The pharmacokinetic advantage relies on the fact that the drug release from 
the fast releasing granules leads to a sudden rise in the blood concentration. 
However, the blood level is maintained at steady state as the drug is released 
from the sustaining granules. 
7. Bilayer tablets help in reducing the fluctuations that arise in the plasma 
concentrations of the drugs. 
8. These bilayer tablets improve patient compliance by reducing the frequency of 
dosing. 
9. Bilayer tablets help in maintaining the chemical and physical integrity of the 
drugs in the layers. 
Disadvantages of bilayer tablets
2,3
:
 
1. Bilayer tablets are mechanically complicated to design or manufacture. 
2. It is harder to predict their long term mechanical properties due to poor 
mechanical and compression characteristics of the constituent materials in the 
adjacent layers 
3. There is a possibility of elastic mismatch of the layers. 
4. Insufficient hardness. 
5. Inaccurate individual mass control. 
6. Reduced yield and tendency to delaminate at the interface between the 
adjacent layers. 
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1.3   COMPONENTS OF BILAYER FORMULATIONS
10
:
 
Bilayer tablets innovates the drug delivery systems by admixing two or more 
drugs in a separate layers and providing as a single unit dosage form. It comprises of 
the following layers.
8 
 Modified release layer 
 Immediate release layer. 
 
1.3.1 Modified release:  
1. Extended – release dosage form: 
A dosage form, which allows at least a two-fold reduction in dosage frequency 
as compared to that drug presented as an immediate release (Conventional) dosage 
form. Examples of extended release dosage forms include controlled release and 
sustained release drug products 
2. Delayed release dosage form: 
 A dosage form that releases a discrete portion or portions of drug at times or at 
time other than promptly after administration, although one portion may be released 
promptly after administration. Enteric-coated dosage forms are the most common 
delayed-release products. 
3. Targeted release dosage form: 
A dosage forms that release drug at or near the intended physiologic site of 
action. Targeted release dosage forms may have either immediate or extended release 
characteristics. 
1.3.2 Immediate Release: 
 Immediate release dosage forms allows drug to dissolve without intention to 
delay or prolong the dissolution or say drug absorption which in turn is the 
consequence of the altered pharmacokinetic parameters of the drug. Drug release 
instantaneously from the fast release granules leads to sudden increase in blood 
concentration. 
15,16. 
1.4 Sustained Release Drug Delivery System: 
  Controlled release pharmaceutical dosage forms have received much attention 
lately. Such controlled release tablets are highly desirable for providing a constant 
level of pharmaceutical agent to a patient. Attempts at controlled release tablets have 
been made in the past, with mixed success 
11 
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Rationale: 
  The basic rationale of a controlled drug delivery system is to optimize the 
biopharmaceutic, pharmacokinetic and pharmacodynamic properties of a drug in such 
a way that its utility is maximized through reduction in side effects and cure or control 
of condition in the shortest possible time by using the smallest quantity of drug, 
administered by most suitable route
12 
 
Advantages of sustained release systems
13
: 
1. Sustained blood levels: The size and frequency of dosing is determined by 
the pharmacodynamic and pharmacokinetic properties of the drug. The slower 
the rate of absorption, the less the blood concentrations fluctuate within a 
dosing interval. This enables higher doses to be given less frequently. For 
drugs with relatively short half-lives, the use of extended release products may 
maintain therapeutic concentrations over prolonged periods. 
2. Attenuation of adverse effects: With conventional dosage forms, high peak 
blood concentrations may be reached soon after administration with possible 
adverse effects related to transiently high concentration. The use of extended 
release formulations avoids the high initial blood concentrations which cause 
the sudden reduction in the blood pressure. 
3. Improved patient compliance: Drugs with short biological half lives need to 
be given at frequent intervals to maintain blood concentrations within the 
therapeutic range. The frequency of dosing and patient compliance is inversely 
related. Reduction in fluctuation in steady state levels and therefore better 
control of disease condition and reduced intensity of local and systemic 
effects. 
4. Increased safety margin of high potency drugs due to better control of plasma 
levels. 
5. Maximum utilization of drug enabling reduction in total amount of dose 
administered. 
6. Reduction in health care costs through improved therapy, shorter treatment 
period, less frequency of dosing and reduction in personal time to dispense, 
administer and monitor the patient. 
7. Opportunities for product differentiation, product life-cycle management, 
market expansion and patent expansion. 
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Disadvantages of sustained release forms
 11,13, 14
: 
1. The necessity to ensure that drug leakage, and other factors which would 
cause  inadequate control and possibly lead to dangerous situations, do not 
occur. 
2. Administration of sustained release medication does not permit the prompt 
termination  of the therapy.  
3. The necessity to ensure the adequate safety of the devices with respect to 
device  components and their degradation products together with the 
biocompatibilities of the  actual devices. 
4. Sufficiently large dose to accommodate the longer dosing interval. 
5. These dosage forms being  bulkier than the immediate release analogs, larger 
proportion of release controlling excipients need to be incorporated. 
6. Possibility of dose dumping due to food, physiological factors or formulation 
variables and thus increased risk of toxicity. 
 
1.4.1 Suitable candidates for sustained release formulations
13,17
: 
The extent of fluctuation in drug concentration at steady state is determined by 
the relative magnitude of the elimination half life and dosing interval. If a drug is 
given at an interval equal to the elimination half life, there is a two-fold difference 
between the maximum and minimum concentrations at steady state. 
1. Drugs with short half lives and with a clear relationship between concentration 
and response. 
2. Higher doses at less frequent intervals will result in higher peak concentrations 
with the possibility of toxicity. 
3. They should possess narrow safety margin. 
4. Chemically incompatible drugs. 
5. Chemically different drugs with same therapeutic activity. 
 
1.4.2 Types of oral extended release systems
19,20
: 
 A survey of commercial Extended release oral solid products indicates that 
most systems fall into one of three broad categories: matrix, reservoir (or membrane 
controlled), and osmotic systems. 
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Matrix systems: 
The matrix system has been most widely utilized to provide extended delivery 
of drug substances because of its effectiveness and the capability of accommodating 
both low- and high-loading of drugs with a wide range of physical and chemical 
properties. 
In a matrix system, the drug substance is homogeneously mixed into the rate-
controlling material(s) and other inactive ingredients as a crystalline, amorphous or, in 
rare cases, molecular dispersion. Drug release occurs either by drug diffusion and /or 
erosion of the matrix system. 
  Based on the characteristics of the rate-controlling material, the matrix system 
can be divided into 
(a) Hydrophilic matrix systems  
(b) Hydrophobic matrix systems 
 
1.4.3 Mechanism of drug release from matrices
18
: 
After oral administration and exposure to the aqueous medium,  
 
                      Hydration of the polymer on the surface of the tablet 
                                                         
                     Formation of a gel layer around the tablet 
                                                        
              Attainment of dilution point by the outermost gelled layer   
 
         Loss of structural integrity, disetanglement of the polymer and erosion 
 
As solubility of the drug reduces, erosion mechanism becomes more prominent. 
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  Fig No.1  Drug release mechanism from a matrix tablet. 
 
1.5 Multi-Particulate Systems
21,25
: 
 Multi-particulate systems often employ pH-sensitive, enteric, or sustained 
release coatings upon aggregate or non-pareil granules of the API. These granules 
may then be packaged in a capsule or compressed with additional excipients to form a 
tablet. The API may also be blended or granulated with polymers before coating to 
provide an additional level of control; these systems may also appear as a blend of 
coated-beads with differing release rates for extended release or pulsitile release 
formulations. Regardless of the manner of manufacture, coated bead systems are 
extremely complex to produce, requiring large numbers of excipients, use of solvents 
and multiple manufacturing steps. 
 
1.5.1 Tabletting Of Multiparticulate Systems
22,23,25
: 
 With regards to the final dosage form, multiparticulates can be filled into hard 
gelatine capsules or be compressed into tablets of which former is commen. Though 
multiparticulates can be filled into hard gelatine capsules, tablet formulation is 
preferred one because of various advantages associated with it. However, 
compression of coated multiparticulates is a challenging task necessitating the 
optimisation of various formulations and process variables. 
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Advantages
24,25
: 
1. Multipartculate units well distribute along the GIT that could improve the      
bioavailability,which potentially could result in a reduction in local drug 
concentration, risk of toxicity, and side effects. 
2. Inter and intra-idividual variations in bioavailability caused by, for example 
food effects, are reduced. 
3. Premature drug release from enteric-coated dosage forms in the stomach, 
potentially resulting in degradation of drug or irritation of gastric mucosa, can 
be reduced with coated multiparticulate units because of more rapid transit time 
when compared to enteric coated tablets. 
4. Administration of incompatible drugs in a single dosage unit by separating them 
in different multiparticulates and combination of multiparticulates with different 
release rates to obtain the desired overall release rates. 
5. Tablets fron multiparticulate units are prepared at low cost when compared to 
multiparticulae units filled into capsules because of the higher production rates 
of tablets. 
6. Reduced risk of tampering and lower tandency of adhesion of dosage form to 
esophagus during swallowing. 
 
Disadvantages
21,22
: 
The main disadvantage is the the compaction of pellets into tablets is a 
complex technology involving various manufacturing steps. 
 
1.5.2 Types
26
: 
Two categories of MUPS are possible, considering that the multiparticulate 
units to be compressed are modified release or have a specific dissolution profile – 
1. Multiparticulate units comprising of polymer coating. 
2. Multiparticulate units comprising of polymer matrix. 
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   Fig No.2 Types of Multiparticulate unit systems. 
1.5.3 Challenges in the Compression of Multiparticulate units into Tablet
21,25
: 
 Compression of multiparticulates into tablets is a challenging task as the 
polymer coatig may not withstand the compression force and the drug release may 
vary due to the unpredictable concentration of the deposited polymer left after 
compaction process and altered surface area during in-vivo dissolution. The 
optimisation of various process variables like compression force required, velocity of 
the punches, hardness, thickness and porosity of the tablets to be maintained is 
required. 
 Factors to be Considered
25,26
 : 
Formulation Variables 
Multiple unti core: 
o Type – matrix or reservoir 
o Composition – hard brittle e.g. sucrose or plastic, e.g. MCC 
o Size 
o Shape 
o Porosity 
o Elasticity – is directly related to pellet composition 
Membrane coating: 
o Type of polymer – cellulosic or acrylic, etc. 
o Coating thickness 
o Type and amount of placticizer 
o Presence of pigments 
o Additional outer coat on polymer surface – plastic layer or powder 
layer 
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Cushioning excipients: 
o Nature – deformable (plastic) or fracturable (brittle) 
o Size – powder or pellets 
o Amount – ideally 50 to 75% 
Process variables: 
o Compression force 
o Compression speed 
Equipment variables: 
o Design of tabletting machine, powder feeding mechanism, etc. 
 
1.6 Challenges in formulation of bilayer tablets
27,28
: 
One of the major challenges is lack of sufficient bonding and adhesion at the 
Interface between the adjacent compacted layers which is often the result of an 
interfacial crack driven by residual stresses in the tablet propagating a finite distance 
within the tablet and leads to delamination (layer-separation) which may not always 
be apparent immediately after compaction (e.g., during storage, packaging, shipping). 
In addition, if the compacted layers are too soft or too hard, they will not bond 
securely with each other which can lead to compromised mechanical integrity. 
Other challenges during development include establishing the order of layer 
sequence, layer weight ratio, elastic mismatch of the adjacent layers, first layer 
tamping force, and cross contamination between layers. These factors, if not well 
controlled/optimized, in one way or another will impact the bilayer compression per 
se (inefficient or uncontrolled process) and the quality attributes of the bilayer tablets 
(sufficient mechanical strength to maintain its integrity and individual layer weight 
control). Therefore, it is critical to obtain an insight into the root causes to enable 
design of a robust product and process. 
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1.6.1 Limitations: 
Limitations in single sided press
29
: 
 Various types of bi-layer presses have been designed over the years. The 
simplest design is a single-sided press with both chambers of the double feeder 
separated from each other. The limitations of such single-sided press are: 
 No weight monitoring/control of the individual layers 
 No distinct visual separation between the two layers 
  Very short first layer-dwell time due to the small compression roller, possibly 
resulting in poor de-aeration, capping and hardness problems. This may be 
corrected by reducing the turret-rotation speed (to extend the dwell time) but 
with the consequence of lower tablet output. 
  Very difficult first-layer tablet sampling and sample transport to a test unit for 
in-line quality control and weight recalibration. 
 To eliminate these limitations, a double sided tablet press is preferred over a 
single sided press.  
 Limitations of “compression force” - controlled tablet presses: 
 Separation of the two individual layers is the consequence of insufficient 
bonding between the two layers during final compression of the bi-layer tablet. 
Correct bonding is only obtained when the first layer is compressed at a low 
compression force so that this layer can still interact with the second layer 
during final compression of the tablet.  
1.6.2 Recommended ways to overcome the limitation
27,29
: 
 Displacement-monitoring/control system for bi-layer compression 
 Tablet weight control using ‘displacement’ is based on the measurement of 
thickness 
 Variations under constant force and is measured at pre-compression. This 
measurement is possible when using the so-called ‘pneumatic compensator’. 
 The displacement-tablet weight control principle is fundamentally different 
from the principle based upon compression force. When measuring 
displacement, the control system’s sensitivity does not depend on the 
operating point on the graph (i.e. it does not depend on the tablet weight) but 
depends on the applied pre compression force.  
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1.7 DISESE PROFILE 
Gastroesophageal reflux disease (GERD): 
Gastroesophageal reflux disease (GERD) is a condition in which the stomach 
contents (food or liquid) leak backwards from the stomach into the esophagus (the 
tube from the mouth to the stomach). This action can irritate the esophagus, causing 
heartburn and other symptoms. 
1.7.1 Symptoms
30,31
: 
 Feeling that food may be left trapped behind the breastbone. 
 Heartburn or a burning pain in the chest (under the breastbone). 
 Increased by bending, stooping, lying down, or eating. 
 More likely or worse at night. 
 Relieved by antacids. 
 Nausea after eating. 
 
 
 
 
 
Fig No.3 Reflux of stomach contents into Esophagus during GERD 
Causes Of GERD
31,32
: 
The cause of GERD is complex. The factors that contribute to GERD are the 
lower esophageal sphincter, hiatal hernias, esophageal contractions, and emptying of 
the stomach. 
1.7.2 Treatment
30,31
: 
 One of the simplest treatments for GERD is referred to as life-style changes, a 
combination of several changes in habit, particularly related to eating. 
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GERD Diet: 
             Certain foods are known to reduce the pressure in the lower esophageal 
sphincter and thereby promote reflux. These foods should be avoided and include 
chocolate, peppermint, alcohol, and caffeinated drinks.  
Antacids: 
 Antacids neutralize the acid in the stomach so that there is no acid to reflux. 
Antacids may be Aluminum, Magnesium, or Calcium based. 
Histamine antagonists: 
The first medication developed for more effective and convenient treatment of 
acid-related diseases, including GERD, was a histamine antagonist, specifically 
Cimetidine. Four different H2 antagonists are available by prescription, including 
Cimetidine , Ranitidine , Nizatidine , and Famotidine. 
Proton pump inhibitors: 
The second type of drug developed specifically for acid-related diseases, such 
as GERD, was a proton pump inhibitor (PPI), specifically, Omeprazole. Five different 
PPIs are approved for the treatment of GERD, including Omeprazole ,Lansoprazole , 
Rabeprazole , Pantoprazole , and Esomeprazole . 
Pro-motility drugs: 
Pro-motility drugs work by stimulating the muscles of the gastrointestinal 
tract, including the esophagus, stomach, small intestine, and/or colon. One pro-
motility drug, Metoclopramide  is approved for GERD.  
Foam barriers: 
Foam barriers are tablets that are composed of an antacid and a foaming agent. 
There is only one foam barrier, which is a combination of Aluminum hydroxide gel, 
Magnesium trisilicate, and Alginate. 
Surgery: 
Sometimes drugs described above are not effective in treating the symptoms 
and complications of GERD. For example, despite adequate suppression of acid and 
relief from heartburn, regurgitation, with its potential for complications in the lungs, 
may still occur. In such situations, surgery can effectively stop reflux. 
 
Chapter 2        
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2. LITERATURE REVIEW 
 
Murat Tu rkoglu et al., (2004) studied fluidized-bed manufactured enteric-coated 
Omeprazole pellets were compressed into tablets. The stability of the pellets and those 
of compressed tablets were evaluated for remaining Omeprazole and for degradation 
products under an accelerated stability protocol. It was found that enteric-coated 
Omeprazole pellets could be compressed into quickly disintegrating tablets using 
microcrystalline cellulose granules as the pressure absorbing matrix. Microcrystalline 
cellulose matrix showed a strong plastic deformation and all the pellets inside the 
tablet maintained their integrity with no significant change in their surface properties. 
 
Baykara et al., (2005) developed Acetaminophen granules by coating with a special 
test and odour masking Acrylate polymer, EudragitE30D with FBP. Then by direct 
compression method, tablet of these granules were prepared and consolidation and 
compressibility properties as well as in-vitro release studied were investigated. 
 
Roland Bodmeier et al., (1994) discusses the important formulation and process 
parameters necessary to obtain pellet-containing tablets, which, ideally, have the same 
properties, in particular drug release properties, as the individual coated pellets. 
Various formulation and process parameters have to be optimized in order to obtain 
tableted reservoir-type pellets having the same properties, and, in particular, release 
properties as the original, uncompacted pellets. 
 
Horst  Zerbe et al., (2007) presented invention related to a multilayer pharmaceutical 
oral dosage form having delayed and immediate release properties and method of 
making the same. The delayed dosage formulation subsequentially behaves as an 
enterically dosage form but without formulation and application of enteric coating. 
The delayed release form is charecterised by a mixture of one or more active 
ingredients and one or more excepients selected from the group of solid aliphatic 
alcohols, mixture of esters of saturated fatty acids,neutal or synthetic waxes, 
hydrogenated vegetable oils,gums,and mixtures thereof. 
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Wu et al., (2008) studied the compaction behaviour of bilayer tablet by using two 
pharmaceutical excipient, Microcrystalline Cellulose and Lactose is investigated. The 
effect of composition and compaction pressure on the compaction behaviour of bi 
layer tablet are explored. In this study it was also observed that using the same 
compaction process, the relative density of the tablets were generally different when 
different composition were used, especially when maximum compression pressure is 
relatively low. In this study they found that, for bi layer tablet with different 
composition delamination or horizontal branches of cracks that may lead to 
delamination occurs when the tablet is compressed with high maximum compression 
force 
 
Viena Dias et al., (2007) investigate drug release from compressed multiple-unit 
pellet systems, coated with an aqueous ethylcellulose dispersion (Surelease
® 
E-7-
19040).  In order to protect the integrity of coated pellets, excipients with protective 
(cushioning) properties are incorporated into tablet formulations. Inclusion of 60-70% 
cushioning granules into the MUPS resulted in hard tablets with low friability and 
consistent drug release profiles. 
 
Podeczeck et al., (2008) studied the tensile strength of bi layer tablet using material 
dicalsium phosphate, microcrystalline cellulose, and Pregelatinised starch and 
compared to from tablets in the form of beam containing of two layers of equal 
thickness. It is found that microcrystalline cellulose as fracture propagated across the 
boundary between the layer. 
 
Dashevsky et al., (2005) worked on the compression of pellets coated with various 
aqueous polymer dispersions pellets coated with a new aqueous polyvinyl acetate 
dispersion, kollicoat sr 30 d, could be compressed into tablets without rupture of the 
coating providing unchanged release profiles. In contrast, the compression of pellets 
coated with the ethyl cellulose dispersion, aqua coated 30, resulted in rupture of the 
coating and an increase in drug release. 
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Guo et al., (2002) investigate the phenomena related to the compression behaviour 
and enteric film coating properties of pharmaceutical cellulose esters. The particle 
deformation in the tablet compression and drug diffusion of film-coated pellets were 
studied. Cellulose esters without any co-diluent (MCC) are not able to produce 
satisfactory direct compressed tablets either because of capping or poor flowability 
during mechanical compression. 
 
Dannielle Combessis et al., (2005) patented an invention related to a multiparticulate 
tablet with improved gastro-protection comprising at least a pharmaceutical active 
substance in the form of enteric coated particles, and a mixture of tableting 
excepients. Accordimg to one embodiment of the invention, the active substance is 
Omeprazole or Esomeprazole. According to another embodiment in the tablet is a 
disintegrating tablet, which disintegrate in the mouth with or without chewing. 
 
Remon et al., (2002) developed film-coated Diltiazem pellets to evaluate them as 
cushioning agents during tabletting in order to protect the film coat from damage. The 
cushioning properties of a-lactose monohydrate granules, microcrystalline cellulose 
pellets and wax/ starch beads were evaluated by comparing the dissolution profile of 
the coated pellets before and after compression. This study demonstrates that adding 
deformable wax pellets minimizes the damage to film-coated pellets during 
compression. 
 
Patel Mehul et al., ( 2005) done a review article which explains why the development 
and production of quality bi-layer tablets needs to be carried out on purpose-built 
tablet presses to overcome common bi-layer problems, such as layer-separation, 
insufficient hardness, inaccurate individual layer weight control, cross-contamination 
between the layers, reduced yield, etc. Using a modified tablet press may therefore not 
be your best approach in producing a quality bi-layer tablet under GMP-conditions. 
Especially when high production output is required. 
 
Goran Alderborn et al., (2003) investigate the influence of the size and the porosity 
of excipient microcrystalline cellulose (MCC) particles on the densification and the 
deformation during compaction and the consequent effect on the drug release from 
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reservoir pellets. Drug pellets consisting of salicylic acid and microcrystalline 
cellulose were prepared by extrusion spheronisation and spray-coated with ethyl 
cellulose (ethanol solution). The reservoir pellets were shown to undergo extensive 
deformation and densification during compaction, resulting in a preserved or even 
prolonged drug release time. 
 
Peter C Schmidt et al., (1996) developed enteric coated sucrose pellets containing a 
layer of bisacodyl beneath the coating were compressed into a tablet on an 
instrumented single punch machine using four different filler binders for direct 
compression. Different copolymers based on polymethacrylates were applied as 
coatings. Results indicate that the most important parameters are the coating agents 
itself and amount of coating applied to the pellets. High coating weights and coatings 
with better elatic properties lead to formulations, which liberate less bisacodyl after 
compression.  
 
Jean-Paul Remon et al., (2010) developed Omeprazole pellets containing mucoadh- 
esive tablets were developed by direct compression method. Three mucoadhesive 
polymers namely HPMC K4,Na CMC, Carbopol-934P and Ethyl cellulose were used 
for preparation of tablet. It concluded that, Carbopol-934P containing mucoadhesive 
tablets of Omeprazole pellets can be used for local action inthe ulcer disease. 
 
Go ran Alderborn et al., (1999) investigated the effect of incorporating a soft 
material (polyethylene glycol; PEG) into pellets of microcrystalline cellulose (MCC) 
on the compression behaviour and compact ability of the pellets. Low and high 
porosity MCC pellets were formed. The lowest total tablet porosity was seen with 
tablets made from pellets containing PEG. The inter granular porosity and the 
permeability of these tablets were similar to those of tablets made of the high porosity 
MCC pellets. 
 
Sunil Jaiswal et al., (2010) provides an update on this research area and discusses the 
phenomena and mechanisms involved during compaction of multiparticulate system 
and material and/or process-related parameters influencing tabletting of 
multiparticulates to produce multiple-unit pellet system (MUPS) or pellet-containing 
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tablets, which are expected to disintegrate rapidly into individual pellets and provide 
drug release profile similar to that obtained from uncoated pellets. 
 
Sumnu et al., (1999) studied about various coating solutions prepared in different 
concentrations and applied to previously subcoated omeprazole tablets to examine 
whether this coating prevented Omeprazole from degrading in acidic media. For 
formulation consideration, the most promising results were obtained from HPMCP4 
and CAP4 (4% enteric coating with hydroxypropylmethyl cellulose phthalate solution 
and cellulose acetate phthalate solution, respectively). 
 
De-Ying et al., (2009) developed a drug-layered or drug-containing core pellets 
coated with salt (sodium chloride and disodium hydrogen phosphate), hydroxypropyl 
methyl cellulose (HPMC), and enteric film-coating layer, respectively. The multi-
layer coated pellets were stable in gastric pH conditions and upper gastrointestinal 
(GI) tract in rats. Salt layer improved the drug stability, and its coating levels had little 
influence on the dissolution profiles of Omeprazole. The drug-layered pellets with 
multilayer film coatings not only provided delayed and rapid release of Omeprazole, 
but also could provide a good stable property for Omeprazole. 
 
Chuanbin Wu et al., (2010) developed a concept of admixing coated pellets with 
excipients to obtain a segregation-free combination of pellet-containing granules and 
cushioning granules during mixing and compression. Compared with the tablets 
directly compressed from coated pellets, the tablets prepared by pellet-containing 
granules showed improved uniformity in both weight and drug content. The 
granulation and compression processes did not significantly influence the drug-release 
behavior of coated pellets, and the enteric dissolution was retained. 
 
Bhupendra Prajapati et al., (2010) has prepared fast dissolving tablets of 
Domperidone by wet granulation. In the present research study, Sodium Starch 
Glycolate, was taken as super disintegrant and starch paste as a binder for the study. 
Here the Domperidone (anti-emetic) is taken as the model drug for the study and wet 
granulation as a method for preparation of the Fast Dissolving Tablet.  
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Horn et al., (2005) has prepared a Review article on similarities and differences 
among delayed-release proton-pump inhibitor formulations. Similarities and 
differences between the various formulations of delayed release proton-pump 
inhibitors. Delayed-release Omeprazole and delayed-release Lansoprazole have been 
suspended in sodium bicarbonate for tube administration. 
 
Prajapati et al., (2009) worked on the matrix tablets of Domperidone were developed 
to prolongation of the gastric residence time of the drug and there by increase the drug 
bioavailability. The tablets were prepared by using different polymers by wet 
granulation technique. 
 
Sanchez Rojas et al., (2007) done on review for estimation of Omeprazole in 
formulations and biological fluids by a variety of methods such as spectrophotometry, 
high-performance liquid chromatography with ultraviolet detection and liquid 
chromatography coupled with tandem mass spectrometry. The overview includes the 
most relevant analytical methodologies used in its determination since the origin still 
today. 
 
Gerald Proehl et al., (2005) developed pharmaceutical formulations containing a 
proton pump inhibitor, one or more buffering agents, and a prokinetic agent. Methods 
are described for treating gastric order disorders, using pharmaceutical compositions 
comprising a proton pump inhibitor, one or more buffering agents, and a prokinetic 
agent. 
 
Rajasekhar et al., (2009) simple and sensitive spectrophotometric method has been 
developed for the estimation of Domperidone in bulk and pharmaceutical 
formulations. The estimation of Domperidone was carried out on a UV/VIS 
spectrophotometer (Analytical technologies) using 1 cm quartz cell.. This method is 
extended to pharmaceutical additive and diluents. The results have been validated 
statistically and recovery studies confirmed the accuracy of proposed method. 
 
Bhavesh Patel et al., (2007) developed a rapid, simple, and sensitive HPLC and a 
densitometric HPTLC method for the determination of Omeprazole and Domperidone 
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in capsule formulations were developed and validated. For HPLC, the separation of 
components was achieved on a Phenomenex Rp-C18 column. Isocratic elution with a 
mobile phase consisting of 0.01 M pH 6.5, ammonium acetate buffer: methanol: 
acetonitrile (40:30:30 v/v, pH 7.44+0.02), at a flow rate 1.0 mL/min was employed. 
The proposed method is applicable for routine determination of omeprazole and 
domperidone in pharmaceutical formulations. 
 
Lakshmi Sivasubramanian et al., (2007) presented a work which describes a simple 
redverse phase HPLC method for the determination of Omeprazole and Domperidone 
tablet formulations. The determination was carried out on a Hypersil, ODS, C-18 
column using a mobile phase of methanol: 0.1 M ammonium acetate (pH 4.9) (60:40). 
The eluent was monitored at 280 nm. The method was reproducible, with good 
resolution between Omeprazole and Domperidone. 
 
Jean-Paul Remon et al., (2004) investigate the influence of formulation and 
compression parameters on the properties of tablets, containing enteric-coated pellets, 
and on the integrity of the enteric polymer of the individual pellets after compression. 
Tablets consisted of enteric-coated pellets (containing 2.5% (w/w) piroxicam in 
combination with microcrystalline cellulose and sodiumcarboxymethylcellulose 
(using Avicel® PH 101 and Avicel® CL 611 in a ratio of 1–3)), cushioning waxy 
pellets From the D-optimality experimental design it was concluded that the ratio of 
coated pellets to cushioning pellets (CoP/CuP) affected all tablet properties evaluated. 
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3. AIM AND OBJECTIVE 
 
3.1 Aim: 
 The main aim of the present work is to develop and evaluate bilaye tablet 
containing compressed Multiparticulate delayed release Omeprazole layer and 
Domperidone Sustained release layer. 
 
Objectives: 
 The main objective of the present work is to develop poly therapy for the 
treatment of Gastroesophageal reflux disease (GERD) by using Omeprazole and 
Domperidone. 
 To achieve FDC in simplest manner of Drug Delivery System. 
 To prepare Bilayer tablets by using compressible enteric coated granules of 
Omeprazole and sustained release granules of Domperidone. 
 To evaluate the resistance to rupture of different enteric coating polymers to 
compression force. 
 To maintain the drug concentration in blood for a longer time. 
 To study the stability of dosage form and compare with the standard 
specifications. 
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4. PLAN OF WORK 
1. To carry out brief literature review 
2. Procurement of API and Excipients 
3. Preformulation Studies 
4. Drug excipients compatibility studies 
 Physical characterisation 
 IR Studies 
5. Analytical method development for the drug  
6. Formulation of blend for tablet 
7. Precompression evaluation 
 Angle  of  repose 
 Bulk Density 
 Tapped Density 
 Hausner Ratio 
 Compressibility Index  
8. Formulation of bilayer Tablets  
9. Evaluation of Formulated Tablets 
 Weight Variation 
 Thickness 
 Hardness 
 Friability 
 In- vitro Dissolution studies 
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10. Elucidation of release kinetics  
11. Elucidation of transport mechanism 
12. Similarity and dissimilarity factor assessment 
13. Comparison with innovator brands 
14. Stability Studies. 
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5. DRUG PROFILE 
OMEPRAZOLE 
Generic name : Omeprazole 
Class   : Proton Pump Inhibitor 
Structure  : 
 
 
 
 
Chemical Name :  5-methoxy-2-[[(4-methoxy 3,5 dimethylpyridin2yl)methyl] 
                                        Sulfinyl]-1H-benzimidazole     
Molecular formula :  C17H19N3O3S 
Molecular weight :  345.4g /mol 
Description  :  Omeprazole is a white to off-white crystalline powder 
Solubility  : Freely soluble in ethanol and methanol, slightly soluble in 
       acetone and isopropanol and very slightly soluble in water 
Standards  :  Omeprazole contains not less than 99.0 per cent and not  
       more  than 101.0 per cent of Omeprazole. 
Heavy metals  :   Not more than 20ppm 
Sulphated Ash :   Not more than 0.2 %,  
Loss on drying :   Not more than 0.2% 
Pharmacological profile
34
: 
  Omeprazole, a gastric acid pump inhibitor. the drug has greater antisecretory 
activity than histamine H2-receptor antagonists. in the maintenance therapy of 
duodenal ulcer,gastric ulcer and reflux esophagitis. Omeprazole binds to hepatic 
cytochrome P450 and inhibits oxidative metabolism of some drugs, the most 
important being phenytoin. 
Mechanism of action
34
:  
 Omeprazole , the substituted benzimidazoles, suppress gastric acid secretion 
by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of 
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the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) 
pump within the gastric mucosa, Omeprazole has been characterized as a gastric acid-
pump inhibitor, in that it blocks the final step of acid production. This effect is dose-
related and leads to inhibition of both basal and stimulated acid secretion irrespective 
of the stimulus. 
Pharmacokinetics
43
:  
1. Absorption:  
Omeprazole is rapidly absorbed from the gut. Peak serum levels occur within 
0.5 to 3.5 hours and onset of action occurs  within 1 hour. Bioavailability is 35-76%. 
The half-life of Omeprazole is short, 0.5-1 hour. 
2. Distribution:  
 Omeprazole is distributed widely, but primarily in gastric parietal cells. In 
humans, approximately 95% is bound to albumin and alpha1-acid glycoprotein. The 
apparent volume of distribution of Omeprazole is about 0.3 to 0.4 L/kg. 
3. Metabolism:  
 Omeprazole is completely metabolized by the cytochrome P450 system, 
mainly in the liver. Identified metabolites are the sulfone, the sulfide and hydroxy-
Omeprazole, which exert no significant effect on the acid secretion.  
4. Elimination: 
 About 80% of an orally given dose is excreted as metabolites in the urine and 
the remainder is found in the feces, primarily originating from bile secretion. 
ADME of Omeprazole: 
   Table No.1  ADME of Omeprazole: 
Oral absorption 32.5%  
Pre systemic metabolism 20% 
Volume of distribution 0.3 - 0.4 L/kg 
Plasma protein binding 95% 
Tmax 0.5 to 3.5 hrs 
Pka 4 , 8.8 
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Drug interactions
44
:  
 As Omeprazole can inhibit the cytochrome P-450 enzyme system, Omeprazole 
may decrease the hepatic clearance of diazepam, phenytoin or warfarin, thereby 
enhancing their effects and causing potential toxicity. 
 Because Omeprazole can increase gastric pH, drugs that require low gastric pH for 
optimal absorption (e.g., ketoconazole, ampicillin esters or iron salts) may have 
their absorption reduced. 
 PPIs are metabolized to varying degrees by the hepatic cytochrome P-450 
enzymatic system and may alter drug metabolism by induction or inhibition of the 
cytochrome P enzymes. This is an important consideration in patients taking 
medications with a narrow therapeutic window, such as diazepam (Valium), 
phenytoin (Dilantin), and warfarin (Coumadin).  
 
Adverse Reactions
43,44
:  
 The most common adverse effects are headache, diarrhea, abdominal pain, and 
nausea. 
 The severe or irreversible adverse effects of Omeprazole, which give rise to 
further complications include Epidermal necrolysis, Renal failure, Interstitial 
nephritis, Fulminant hepatic failure. 
Therapeutic use
43
 
 Treatment of gastric ulcer (GU), erosive esophagitis (EE), gastroesophageal reflux 
disease (GERD) with or without esophageal lesion.  
 Maintenance therapy of EE.  
 Eradication of Helicobacter pylori in triple therapy with clarithromycin and 
amoxicillin or in double therapy with clarithromycin only.  
Overdosage/Toxicology
44
:   
 Symptoms of overdose include confusion, drowsiness, blurred vision, 
tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other 
adverse reactions similar to those seen in normal clinical experience. Treatment for an 
overdose of Omeprazole will likely involve supportive care. 
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Dosage and Administration:  
 PPIs are inactivated by exposure to gastric juice and are delivered in delayed-
release forms. Omeprazole is supplied in doses of 10, 20, and 33 mg.It should be 
taken 30 minutes before meals. 
 The usual oral adult dosage of Omeprazole seems to be 20mg once daily before 
breakfast for 2 to 4 weeks for DU,GERD and 4 to 8 weeks for GU,EE. 
 In patients with Zollinger-Ellison syndrome it is 60mg. 
Special Precautions: 
 Omeprazole is contraindicated in patients hypersensitive to it. Increased 
embryo-lethality has been noted in lab animals at very high dosages. 
Stability: 
 Stored below 33°C, should be kept away from moisture and light. 
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DOMPERIDONE 
Generic name :  Domperidone 
Class   :  Dopamine-2 receptor antagonist 
Structure  : 
 
 
 
 
Chemical Name : 5-chloro-1-[1-[ [3-(2-oxo-1,3-dihydrobenzoimidazol-1-   
                                       yl)propyl]-4-piperidyl]-1,3-dihydrobenzimidazol-2-one. 
Molecular formula : C22H24ClN5O2 
Molecular weight : 425.911g/mol 
Description  : A white or almost white powder. 
Solubility  : Soluble in dimethyl formamide, slightly soluble in 
      methanol, practically insoluble in water 
Standards  :  Domperidone contains not less than 99.0 per cent and not  
                                        More than 101.0% of Domperidone 
Heavy metals  :  Not more than 20ppm 
Sulphated Ash :  Not more than 0.1 %,  
Loss on drying :  Not more than 0.5% 
Pharmacological profile
33
:  
 Domperidone is a dopamine-2 receptor antagonist. It acts as an antiemetic and 
a prokinetic agent, Domperidone elevates serum prolactin concentrations. 
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Mechanism of action
33
:  
 The gastroprokinetic properties of Domperidone are related to its peripheral 
dopamine receptor-blocking properties. Domperidone increases esophageal peristalsis 
and facilitates gastric emptying by augmenting gastric peristalsis and by improving 
antroduodenal coordination. The anti-emetic properties of dopamine are related to its 
dopamine (D2) receptor-blocking activity both at the chemoreceptor trigger zone in 
the area postrema and at the gastric level. 
Pharmacokinetics
35,36
:  
1. Absorption:  
 Domperidone is absorbed orally with time of peak serum concentration 30 
minutes, but bioavailability is only ~ 15% due to first pass metabolism. The plasma 
half life is t1/2 is 7 hours. 
2. Distribution:  
 Domperidone is 91-93% bound to plasma protein. Volume of distribution is 
5.71 L/Kg which indicates an extensive distribution of drug in the body. 
3. Metabolism:  
 Domperidone is extensively metabolized in liver the major pathway of 
metabolism is N- dealkylation and hydroxylation catalyzed by cytochrome P 450. 
Metabolites are inactive. 
 
4. Elimination: 
  The metabolites of Domperidone are excreted in urine and feces.  
 ADME of Domperidone:     
       Table No.2  ADME of Domperidone                 
Oral absorption 93% 
Pre systemic metabolism 83-87% 
Volume of distribution 5.71 L/kg 
Plasma protein binding 91-93% 
Tmax 30 min 
Cmax 18.8 ng/ml 
Pka 7.9 
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Drug interactions
37,38
:  
 Concomitant administration of anti-cholinergic drugs may inhibit the anti-
dyspeptic effects of Domperidone. 
 Anti-muscarinic agents and opioid analgesics may antagonise the effect of 
Domperidone. 
 Domperidone suppresses the peripheral effects (digestive disorders, nausea and 
vomiting) of   dopaminergic agonists. 
 As Domperidone interferes with serum prolactin levels, it may interfere with other 
hypoprolactinaemic agents. 
 Antacids and anti-secretory agents lower the oral bioavailability of Domperidone. 
They should be taken after meals and not before meals, i.e. they should not be 
taken simultaneously with Domperidone. 
Adverse Reaction
37,38,39
:  
 Central nervous system: Headache/migraine (1%); does not cross blood-brain 
barrier; fewer CNS effects compared to metaclopramide.  
 Gastrointestinal: Abdominal cramps, constipation, diarrhea, dizziness, dysuria, 
edema, extrapyramidal symptoms (EPS) rarely, galactorrhea, gynecomastia, 
heartburn, hot flashes, increased prolactin, insomnia, irritability, nervousness, 
thirst, lethargy, leg cramps, mastalgia, menstrual irregularities, nausea, palpitation, 
pruritus, rash, regurgitation, stomatitis, urinary frequency, urticaria, weakness. 
Therapeutic uses: 
 Domperidone is a first choice antiemetic in most countries. 
 Domperidone has also been found effective in the treatment of gastroparesis, a 
stomach motility condition, and for paediatric gastroesophageal reflux (infant 
vomiting). 
 For management of dyspepsia,heartburn and epigastric pain. 
Overdosage/Toxicology:   
 Symptoms of overdose include CNS effects (drowsiness, disorientation, and 
extrapyramidal reactions) and cardiovascular effects (arrhythmias and hypotension). 
Treatment is supportive. 
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Dosage And Administration
35,36
:  
 Upper Gastrointestinal Motility Disorders: The usual dosage in adults is 10 mg 
orally 3 to 4 times a day, 15 to 30 minutes before meals and at bedtime if required. 
 Antiparkinsonian Agents: The usual dosage in adults is 20 mg orally 3 to 4 times a 
day. 
Special Precautions: 
 Since Domperidone is highly metabolized in the liver, should be used with 
caution in patients with hepatic impairment (and in the elderly). 
Stability: 
 Store at room temperature of 15°C to 30°C (59°F to 86°F); protect from light 
and moisture.  
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6. EXCIPIENT PROFILE
 
6.1 HYPROMELLOSE
42
 
Non-proprietary Names             
      BP      : Hypromellose 
      JP       : Hypromellose                
      PhEur : Hypromellose 
Synonyms :                               
             Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
hypromellosum;     Methocel; methylcellulose propylene glycol ether; methyl 
hydroxypropylcellulose; Metolose; MHPC; Pharmacoat; Tylopur; Tylose MO. 
            Structure: 
 
 
 
 
 
Chemical Name and CAS Registry Number :                                          
 Cellulose hydroxypropyl methyl ether [9004-65-3].      
Functional Category            
          Bioadhesive material, coating agent, controlled release agent, dispersing agent, 
dissolution enhancer, emulsifying agent, emulsion stabilizer, extended release  agent, 
film forming agent, foaming agent, granulation aid, modified release agent, 
mucoadhesive agent, release modifying agent, solubilising agent, stabilizing agent, 
suspending agent, sustained release agent, tablet binder, thickening agent, viscosity 
increasing agent. 
Description: 
               Hypromellose is an odourless and tasteless, white or creamy white fibrous 
granular powder. 
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Viscosity: 
                          Typical viscosity values for 2% (w/v) aqueous solutions of Methocel (Dow 
Wolff Cellulosics) and Metolose (Shin-Etsu Chemical Co.Ltd.) are given in the 
following table 
         Table No.3 Different viscosity grades of Hypromellose 
 
 Applications in Pharmaceutical formulation or technology; 
           Hypromellose is widely used in oral, ophthalmic, nasal, and topical 
pharmaceutical formulations. 
Uses of Hypromellose: 
  Table No.4 Uses of Hypromellose 
Methocel and Metolose products     Nominal viscosity  (mPa s) 
Methocel K3 Premium LV 3 
Methocel K100 Premium LVEP 100 
Methocel K4M Premium 4000 
Methocel K100M Premium 100000 
Methocel E3 Premium LV 3 
Methocel E5 Premium LV 5 
Dosage form Use 
Oral products Tablet binder, in film coating and as a matrix for 
extended release tablets 
Liquid oral dosage forms Suspending or thickening agent 
Topical formulations Thickening agent 
Ear drops and Tear fluids Thickening agent 
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6.2 LACTOSE MONOHYDRATE
42
 
Nonproprietary Names:  
BP     :  Lactose mono hydrate                                         
USP    :  Lactose monohydrate 
Synonyms      :  Pharmactose ,  Lactochem crystal        
Structure       :  
                           
 
 
 
Chemical Name     :  O-β-d-Galactopyranosyl-(1→4)-α-d- 
                                            glucopyranose monohydrate 
Empirical Formula :  C12H22O11.H2O 
Molecular weight :  360.31 
Description:   
Lactose occurs as white to off-white crystalline particles or powder. Lactose is 
odorless and slightly sweet-tasting, α-lactose is approximately 20% as sweet as 
sucrose, while β-lactose is 40% as sweet. 
Functional categories:  
Binding agent, diluent for dry-powder inhalers, tablet binder, tablet and 
capsule diluent 
Solubility:   
Insoluble chloroform, ethanol, ether and soluble in water. 
Loss on drying :   0.5% 
Applications in Pharmaceutical Formulation or Technology:  
1. Lactose is widely used as a filler or diluent in tablets and capsules. 
2. Lactose is also used as a diluent in dry-powder inhalation. 
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3. Other applications of lactose include use in lyophilized products, where lactose is 
added to freeze-dried solutions to increase plug size and aid cohesion. Lactose is also 
used in combination with sucrose (approximately 1 : 3) to prepare sugar-coating 
solutions 
 
6.3 MANNITOL
42 
Nonproprietary Names: 
          BP     : Mannitol. 
          JP      : D-Mannitol. 
    PhEur      : Mannitolum. 
      USP       : Mannitol. 
Synonyms: 
Cordycepic acid; C PharmMannidex; E421; manna sugar; D-mannite; 
mannite; Mannogem; Pearlitol. 
Structure: 
 
 
 
 
 
Chemical name and CAS registry number: D-Mannitol [69-65-8]. 
Molecular weight: 182.17 
 Description: 
Mannitol occurs as a white, odorless, crystalline powder, or free-flowing 
granules. 
Solubility: 
            Alkalis   :   Soluble 
            Ethanol (95%)  :   1 in 83 
 
Functional Category: 
Diluent; diluent for lyphilized preparations; sweetening agent; tablet and 
capsule diluent; tonicity agent. 
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Applications:  
Used as a diluent (10–90% w/w) in tablet formulations, Mannitol may be used 
in direct-compression tablet applications. Granulations containing mannitol have the 
advantage of being dried easily. Specific tablet applications include antacid 
preparations, glyceryl trinitrate tablets, and vitamin preparations. Mannitol is 
commonly used as an excipient in the manufacture of chewable tablet formulations 
because of its negative heat of solution, sweetness, and ‘mouth feel’. 
 
6.4 MICROCRYSTALLINE CELLULOSE
42
 
Non-proprietary Names:   
             BP         : Microcrystalline cellulose 
             USPNF :  Microcrystalline cellulose 
Synonyms : Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline 
cellulose; E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose. 
Structure: 
 
 
 
Chemical Name and CAS Registry number: Cellulose [9004-34-6] 
Empirical Formula:  (C6H10O5) n where n ≈ 220. 
Functional Category: Adsorbent; suspending agent; tablet and capsule diluent 
Description:  
MCC is purified, partially depolymerised cellulose that occurs as a white, 
odourless, tasteless, crystalline powder composed of porous particles.  
 
Solubility:  
Slightly soluble in 5%w/v sodium hydroxide solution. Practically insoluble in 
water, dilute acids and most organic solvents. 
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Applications in Pharmaceutical Formulation or Technology: 
            Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct compression processes. It also has some lubricant and 
disintegrant properties. 
Incompatibilities: MCC is incompatible with strong oxidizing agents 
 6.5 POVIDONE
42
 
   Non-proprietary Names 
BP       : Povidone 
JP        : Povidone 
PhEur  : Povidone 
USP   : Povidone 
   Synonyms: 
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; 
polyvidone;   polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1- vinyl-2-
pyrrolidinone polymer. 
  Structure: 
 
 
 
 
   Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Functional Category: 
Disintegrant; dissolution enhancer; suspending agent; tablet binder 
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  Description: 
Povidone occurs as a fine, white to creamy-white colored, odourless or almost 
odourless, hygroscopic powder. 
Viscosity: 
   Table No.5 Different viscosity grades of Povidone 
Grade Dynamic viscosity(mPas) 
K-11/14 1.3-2.3 
K-16/18 1.5-3.5 
K-24/27 3.5-5.5 
K-28/32 5.5-8.5 
 
 Applications in Pharmaceutical formulation or Technology: 
    Table No. 6 Uses of Povidone 
Use Concentration 
Carrier for drugs 10-25 
Dispersing agent 5 
Suspending agent 5 
Tablet binder, diluents or coating agent 0.5 
               
 
6.6 HYPERMELLOSE PHTHALATE
42
 
Nonproprietary Names: 
BP  : Hypromellose phthalate 
JP  : Hydroxypropylmethylcellulose phthalate 
PhEur  : Hypromellosi phthalas 
USPNF : Hypromellose phthalate 
 
 Synonyms: 
Cellulose phthalate hydroxypropyl methyl ether; HPMCP; hydroxypropyl 
methylcellulose benzene-1,2-dicarboxylate; 2-hydroxypropyl methylcellulose 
phthalate;methylhydroxypropylcellulose phthalate. 
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Structure: 
 
 
 
 
 
Chemical Name and CAS Registry Number: 
Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl methyl ether 
[9050-31-1] 
Functional Category: Coating agent. 
Description: 
Hypromellose phthalate occurs as white to slightly off-white, free-flowing 
flakes or as a granular powder. It is odorless or with a slightly acidic odor and has a 
barely detectable taste. 
Solubility:  
Readily soluble in a mixture of acetone and methyl or ethyl alcohol (1 : 1), in a 
mixture of methyl alcohol and dichloromethane (1 : 1), and in aqueous alkali. 
Practically insoluble in water and dehydrated alcohol and very slightly soluble in 
acetone. 
Melting point: 150°C. Glass transition temperature is 137°C for HP-50 and 133°C 
for HP-55. 
Moisture content: Hypromellose phthalate is hygroscopic; it takes up 2–5% of 
moisture at ambient temperature and humidity conditions 
Applications: 
Hypromellose phthalate is widely used in oral pharmaceutical formulations as 
an enteric coating material for tablets or granules 
Hypromellose phthalate can be applied to tablet surfaces using a dispersion of 
the micronized hypromellose phthalate powder in an aqueous dispersion of a suitable 
plasticizer such as triacetin, triethyl citrate, or diethyl tartrate along with a wetting 
agent. 
Hypromellose phthalate may be used alone or in combination with other soluble 
or insoluble binders in the preparation of granules with sustained drug-release 
properties; the release rate is pH-dependent. 
Chapter-6                                                                                             Excepient Profile 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode   41 
 
6.7 EUDRAGIT NE 30 D
40
 
Nonproprietary Names: 
Ph.Eur  : Polyacrylate Dispersion 30 Per Cent  
USP/NF : Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion - NF  
JPE            : Ethyl Acrylate Methyl Methacrylate Copolymer Dispersion  
Structure: 
 
 
 
CAS number  : 9010 – 88 – 2  
Chemical/IUPAC name: Poly(ethyl acrylate-co-methyl methacrylate) 2:1 
INCI name: Acrylates Copolymer. 
Molecular weight information: approx. 750,000 g/mol  
Minimum Film Forming Temperature (MFT): ~5°C  
Glastransition Temperature (Tg): -8°C  
Product Form: Aqueous Dispersion 30%  
Targeted Drug Release Area: Time controlled release, pH independent  
Physical properties:  
It is a milky-white liquid of low viscosity with a faint characteristic odour. 
Dissolution: 
     Insoluble 
 Low permeability 
pH independent swelling 
Characteristics: 
    No plasticizer required 
Highly flexible 
        Suitable for matrix structure 
Applications: 
1. pH-dependent drug release 
2. EUDRAGIT® is employed as a coating material, usually for the coating of 
pellets or particles that are filled into capsules or compressed into tablets. 
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These pellets or particles act as diffusion cells in the digestive tract and release 
a constant drug quantity per unit of time (multi-unit dosage forms). 
6.8 KOLLICOAT MAE 30DP
41
 
Nonproprietary Names: 
      Ph.Eur      :Methacrylic acid-ethyl acrylate co-polymer(1:1),30% dispersion 
      USP-NF    :Methacrylic acid co-polymer dispersion 
      JPE           :Methacrylic acid co-polymer LD 
 
Structure: 
 
 
 
 
 
The chemical structure of both Kollicoat MAE grades consists of a 
methacrylic acid-ethyl acrylate co-polymer, the two monomers being bound in the 
molar ratio of 1:1.This is an anionic co-polymer that can be neutralized by bases 
such as sodium hydroxide 
Description: 
 Kollicoat MAE 30DP is a low-viscosity, milk-like white dispersion with a 
solid content of 30%, it has typically slight inherent odour. 
Viscosity          : 15mPa’s 
Solid contents :28.5-31.5% 
Solubility: 
 Kollicoat MAE 30DP is excellently miscible with water in any ratio without losing 
its milky white appearance. Even in a slightly alkaline aqueous medium it forms a clear 
solution. When the organic solution is being initially added, a precipitate is formed; this is 
redissolved on adding further solvent.  
Applications: 
 Kollicoat MAE grades are used in enteric coating of tablets,granules and 
crystals 
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6.9 POLYETHYLENE GLYCOL
42
 
 Nonproprietary Names: 
BP : Macrogols 
JP : Macrogol  
PhEur : Macrogola 
USPNF : Polyethylene glycol 
Synonyms: 
Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; PEG; PluriolE; 
polyoxyethylene glycol. 
Structure: 
 
 
 
 
 
Chemical Name and CAS Registry Number: 
a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) [25322-68-3] 
Empirical Formula and Molecular Weight: 
HOCH2(CH2OCH2)mCH2OH where m represents the average number of 
oxyethylene groups 
 Functional Category: 
Ointment base; plasticizer; solvent; suppository base; tablet and capsule 
lubricant. 
Description: 
 Polyethylene glycol grades 200–600 are liquids; grades 1000 and above are 
solids at ambient temperatures. Liquid grades (PEG 200–600) occur as clear, colorless 
or slightly yellow-colored, viscous liquids. They have a slight but characteristic odor 
and a bitter, slightly burning taste. 
 
Solubility: 
 All grades of polyethylene glycol are soluble in water and miscible in all 
proportions with other polyethylene glycols (after melting, if necessary). Aqueous 
solutions of higher-molecular-weight grades may form gels.  
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 Applications: 
1. Solid grades are generally employed in topical ointments, with the consistency 
of the base being adjusted by the addition of liquid grades of polyethylene 
glycol 
2. Solid grades are also widely used as plasticizers in conjunction with film-
forming polymers. The presence of polyethylene glycols in film coats, 
especially of liquid grades, tends to increase their water permeability and may 
reduce protection against low pH in enteric-coating films. 
3. Polyethylene glycols are useful as plasticizers in microencapsulated products 
to avoid rupture of the coating film when the microcapsules are compressed 
intotablets. 
 
6.10 COLLOIDAL SILICON DIOXIDE
42 
Nonproprietary Names: 
BP  : Colloidal anhydrous silica. 
PhEur  : Silica colloidalis anhydrica. 
USPNF  : Colloidal silicon dioxide. 
Synonyms: 
Aerosil; Cab-O-Sil; Cab-O-Sil M-5P; colloidal silica; fumed silica; light 
anhydrous silicic acid; silicic anhydride; silicon dioxide fumed; Wacker HDK. 
Structure: 
 
 
Chemical name and CAS registry number: Silica [7631-86-9]. 
Molecular weight: 60.08 
 Description: 
It is a light, loose, bluish-whitecolored, odorless, tasteless, nongritty 
amorphous powder. 
Solubility: 
Practically insoluble in organic solvents, water, and acids, except hydrofluoric 
acid; soluble in hot solutions of alkali hydroxide. 
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Functional Category: 
Adsorbent; anticaking agent; emulsion stabilizer; glidant; suspending agent; 
tablet disintegrant; thermal stabilizer; viscosity-increasing agent. 
Applications: 
Widely used in pharmaceuticals, cosmetics, and food products; used to 
stabilize emulsions and as a thixotropic thickening and suspending agent in gels and 
semisolid preparations In aerosols, other than those for inhalation, colloidal silicon 
dioxide is used to promote particulate suspension. 
 
6.11 MAGNESIUM STEARATE
42
 
Nonproprietary Names: 
BP  : Magnesium stearate. 
JP  : Magnesium stearate. 
PhEur  : Magnesii stearas. 
USPNF  : Magnesium stearate. 
Synonyms: 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
Chemical name and CAS registry number: 
Octadecanoic acid magnesium salt [557-04-0]. 
Molecular weight:  591.34.  
 Description: 
Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
Solubility: 
Practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
Functional Category: Tablet and capsule lubricant. 
Applications: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet.  
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6.14 TALC
42 
Nonproprietary Names: 
BP  : Purified talc 
JP  : Talc 
PhEur  : Talcum 
USP  : Talc 
Synonyms: 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
Chemical name and CAS registry number: Talc [14807-96-6]. 
 Description: 
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
Moisture content: 
Talc absorbs insignificant amounts of water at 25ºC and relative humidities up 
to about 90%. 
Solubility: 
Practically insoluble in dilute acids and alkalis, organic solvents, and water. 
Functional Category: 
Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications: 
1. Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent, it is widely used as a dissolution retardant in the development of 
controlled-release products.  
2. Talc is also used as a lubricant in tablet formulations in a novel powder 
coating for extended-release pellets, and as an adsorbant. 
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7. MATERIALS AND METHODS 
7.1 Materials used:  
Table No.7 Materials used in formulation of Omeprazole and Domperidone 
bilayer tablets 
 
  S. No Name of the material   Name of the supplier              Use 
1. Omeprazole Scott Pharma  Ltd. API 
2. Domperidone Scott Pharma  Ltd. API 
3. HPMCK4M Dow Chemicals Polymer 
4. HPMCK15M Dow Chemicals. Polymer 
5. Lactose Sd fine Chem.Ltd Diluent 
6 Mannitol Sd fine Chem.Ltd Diluent 
7 Avicel PH102 FMC Biochemicals Disintegrant 
8 Avicel PH200 FMC Biochemicals Diluent 
9 Povidone Rankem Binder 
10 Na2CO3 Drugs India Pvt Ltd Stabilizer 
11 HPMC P Qualigens fine chemicals Enteric Coating 
12 Eutragit NE30D Qualigens fine chemicals Enteric Coating 
13 KollicoatMAE 30DP Qualigens fine chemicals Enteric Coating 
14 PEG Qualigens fine chemicals Plastisizer 
15 IPA Rankem Solvent 
16 Aerosil DMV Fonterra Absorbent 
17 Magnesiumstearate DMV Fonterra Lubricant 
18 Talc DMV Fonterra Glident 
19 Iron Oxide Roha Dyechem pvt.ltd. Colouring agent 
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 7.2 LIST OF INSTRUMENTS  
         
       Table No.8  Instruments employed in the formulation of bilayer tablet 
 
 
 
 
S.No Name of the Equipment      Manufacturing Company 
1. Weighing balance Electro lab. 
2. Sifter Neo machine. 
3. Rapid mixing granulator Prism Pharma. 
4. Fluid Bed Dryer Pam Glatt. 
5. Octagonal Blender Prism Pharma. 
6. Tapped density Apparatus Electro lab. 
7. 
Double Sided Rotary tablet  Press 27   
station 
Cadmach. India. 
8. Friabilator Electrolab. 
9 Hardness Tester Pharma Test 
10. U.V Spectro Photometer Elic. 
11 HPLC Shimadzu-Corporation, Japan 
12. 
Automatic tablet dissolution 
apparatus USP Type II 
Electro Lab. 
13. pH Meter Eutech 
14. Bath ultra sonicator PCI, Mumbai. 
15. Digital vernier caliperse 
Absolute Digimate,     
industrial stores. 
16. GPCG Gansons 
17. Stability Chamber Prism Pharma. 
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 7.3 PRE-FORMULATION STUDIES
45
 
Prior to the development of the dosage from, it is essential that certain 
fundamental physical and chemical properties of the drug molecule and other derived 
properties of the drug powder are determined. This information dictates many of the 
subsequent events and approaches in formulation development. This first learning 
phase is known as Pre-formulation.  
Pre formulation may be described as a phase of the research and development 
process where the formulation scientist characterizes the physical, chemical and 
mechanical properties of a new drug substance, in order to develop stable, safe and 
effective dosage forms. Ideally, the Pre formulation phase begins early in the 
discovery process such that appropriate physical, chemical data is available to aid in 
the selection of new chemical entities that enter the development process. During this 
evaluation possible interaction with various inert ingredients intended for use in final 
dosage form are also considered. 
Pre-formulation commences when a newly synthesized drug shows sufficient 
pharmacological promise. These studies should focus on those physico-chemical 
properties of the compound that could affect the development of an efficacious dosage 
form. These studies provide a thorough understanding of the properties and ultimately 
provide a rational for the formulation design or support the need for molecular 
modification.  
7.3.1 Organoleptic Properties:
11 
a) Colour:  
A small quantity of powders were taken in butter paper and observed in well-
illuminated place. 
b) Taste and odour:  
Very less quantity of powders is tasted and perceived to observe the odor as 
well. 
Solubility: 
 The approximate solubility of substances are indicated by the descriptive 
terms. Solvents such as Methanol, alcohol   and water and isopropyl alcohol are used 
for the solubility studies.
14 
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                             Table No.9 Official solubility Grades 
Descriptive Term 
Parts of Solvent Required for 1 
part of Solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1,000 
Very slightly soluble From 1,000 to 10,000 
Practically insoluble or Insoluble Greater than or equal to 10,000 
 
7.3.2 Drug excipient compatibility studies
46
: 
Drug Excipients compatibility studies are carried out by mixing the drug with     
various excipients in different proportions (in 1:1 ratio were prepared to have 
maximum likelihood interaction between them) was placed in a vial, and rubber 
stopper was placed on the vial and sealed properly. Studies were carried out in glass 
vials at Accelerated conditions, 40º C ± 2° C / 75% RH ± 5 % RH for a storage period 
of 4 weeks. After storage, the sample was compared with control at 2-8° C and 
observed physically for liquefaction, caking and discoloration. 
7.3.3 IR Studies
47
: 
The IR studies for drug excipient compatibility are mainly meant to confirm 
the integration of the drugs active moiety when combined with the excipients. The 
samples are previously grounded and mixed thoroughly with Potassium bromide and 
compressed through the hydraulic press to form pellets. The spectral smoothening and 
the baseline corrections procedures are done prior to sampling and the sample being 
scanned at 400cm
-1
 to 4000cm
-1
 ambient temperature. 
7.3.4 Particle size distribution:   
The main aim of sieve analysis is to determine the different size of drug 
particles present. A series of standard sieves were stacked one above the other so that 
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sieves with larger pore size (less sieve number) occupy top position followed by 
sieves of decreasing pore size (larger sieve number) towards the bottom. 
Procedure: 
 A series of sieves are stacked one over the other arranged in ascending order 
of increasing mesh number from the top. The stated quantity of powder is placed over 
the top and are tapped mechanically for 15 to 20 minutes.  The powder retained over 
every mesh and pan is weighed and from this the average mean diameter of the 
particles in µm is found by using the following formula, 
Average mean diameter= Σnd/Σx 
Where n= weight of the powder retained in grams  
 d= arithmetic mean size openings in µm 
 x= percentage weight of the powder retained. 
 The same procedure is repeated for all the powders. 
7.4 Analytical method development for Omeprazole and Domperidone: 
Determination of absorption maxima: 
  A spectrum of the working standards is obtained by scanning from 200-400nm 
against the reagent blank to fix absorption maxima. The λmax is found out and all 
further investigations are being carried out at that same wavelength. 
Preparation of Phosphate Buffer pH 6.8: 
Placed 11.45 gms of potassium dihydrogen phosphate and 28.80 gms of 
disodium hydrogen phosphate and made up to 1000 ml with distilled water. 
Preparation of standard graph in pH 6.8 Phosphate buffer: 
Accurately weighed 20 mg of Omeprazole and Domperidone each and  is 
dissolved in 100ml of 6.8 pH phosphate buffer. This is regarded as the primary stock 
solution. From this primary stock solution, 1ml, 2ml, 3ml, 4ml, 5ml and 6ml is 
pipetted out and made up to 100ml with pH 6.8 phosphate buffer, to produce 2µg/ml, 
4µg/ml, 6µg/ml, 8µg/ml, 10µg/ml and 12µg/ml respectively. The absorbance was 
measured at 295 nm by using a UV-Vis spectrophotometer.  
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Characterization of Tablets: 
7.5. Pre compression properties: 
7.5.1 Angle of Repose
49,50,51
:
 
The angle of repose is the maximum angle that the plane of powder makes with 
the horizontal surface on rotation. Angle of repose is helpful in assessment of flow 
properties of particles which could be further related to packing densities and 
mechanical arrangements of particles.
 
           The angle of repose of granules was determined by the fixed funnel and free 
standing cone method. The accurately weighed granules were taken in a funnel. The 
height of the funnel was adjusted in such a manner that the tip of the funnel just 
touched the apex of the heap of the granules. The granules were allowed to flow 
through the funnel freely onto the surface. The diameter of the powder cone measured 
and angle of repose was calculated using the following equation: 
                                                  tan θ = h/r   
              Where,     h = height of the powder  
                                        r = radius of the powder heap 
                                        θ = is the angle of repose. 
 Angles of Repose: 
                Table No.10 Relationship between Angle of repose and Flow property 
  
      S.No Angle of Repose (degrees) Flow Property 
        1 25–30 Excellent 
        2 31–35 Good 
        3 36–40 Fair—aid not needed 
        4 41–45 Passable—may hang up 
        5 46–55 Poor—must agitate, vibrate 
        6 56–65 Very poor 
        7 >66 Very, very poor 
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 7.5.2 Determination of Bulk Density and Tapped Density: 
Bulk density of a compound varies substantially with the method of 
crystallisation, milling or formulation. It is of great importance when one considers 
the size of a high – dose capsule product or the homogeneity of a low dose 
formulation in which there are large differences in drug and excipient densities. In 
addition to bulk density, it is frequently desirable to know the true density of a powder 
for computation of void volume or porosity of packed powder beds. 
  An accurately weighed quantity of the granules/ powder (W) was carefully 
poured into the graduated cylinder and volume (V0) was measured. Then the 
graduated cylinder was closed with lid and set into the tap density tester (USP). The 
density apparatus was set for 100 tabs and after that the volume (Vf) was measured 
and continued operation till the two consecutive readings were equal. The bulk 
density and the tapped density were calculated using the following formulae. 
             Bulk density      = W/V0 
                                               Tapped density = W/Vf 
                            Where,    
                   W = Weight of the powder 
                                             V0 = Initial volume 
                                              Vf = final volume  
  7.5.3 Carr’s Compressibility Index49: 
An indirect method of measuring powder flow from bulk densities was 
developed by Carr. The percentage compressibility of a powder was a direct measure 
of the potential powder arch or bridge strength and stability. Carr‘s index of each 
formulation was calculated according to equation given below:  
  Carr’s Compressibility Index (%)   =      [(TD-BD) X 100] / TD 
   
 
    Where,       
        TD = Tapped density 
                              BD = bulk density 
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Table.No.11  Relationship between Carr‘s index and Flow property 
 
 
 
                  
 
 
 
 
 
      
 7.5.4 Hausner’s Ratio        
                    Hausner‘s Ratio indicates the flow properties of the powder and is 
measured by the ratio of tapped density to bulk density. It is the ratio of tapped density 
and bulk density. Hausner found that this ratio was related to interparticle friction and, 
as such, could be used to predict powder flow properties. Generally a value less than 
1.25 indicates good flow properties, which is equivalent to 20% of Carr‘s index. 
         
   Hausner’s Ratio     =    Tapped density/Bulk Density 
  
  
 
 
 
 
S.No Compressibility Index (%) Flow Character 
1. 
10 Excellent 
2. 11–15 Good 
3. 16–20 Fair 
4. 21–25 Passable 
5. 26–31 Poor 
6. 32–37 Very poor 
7. >38 Very, very poor 
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      Table No.12 Limits of Hausner‘s ratio values as per USP 
 
      S.No Hausner Ratio Flow Character 
        1 1.00–1.11 Excellent 
        2 1.12–1.18 Good 
        3 1.19–1.25 Fair 
        4 1.26–1.34 Passable 
        5 1.35–1.45 Poor 
        6 1.46–1.59 Very poor 
        7 >1.60 Very, very poor 
 
 
7.5.5 Loss on Drying (LOD): 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from water and volatile matter of any kind that can be driven off under specified 
conditions. The test is carried out on a well-mixed sample of the substance. If the 
substance is in the form of large crystals, reduce the size by rapid crushing to a 
powder. 
Procedure: 
Loss on drying is performed using the IR moisture analyzer. 1gm of granules 
was taken and placed in an IR moisture analyzer containing the plate at the centre, 
spread the granules on to the plate uniformly, and adjust  temperature of the analyzer 
at 105
o
C. Switch on the analyzer and wait until the alert sound comes from the 
analyzer, readings was noted down from the digital display. 
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 7.6 THE COMPOSITION OF BILAYER TABLETS PREPARED USING  
OMEPRAZOLE AND DOMPERIDONE: 
 Table No.13 Formulation Code of Omeprazole Layer 
  
 
S.No 
 
Name of the Ingredient 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
 
F6 
Dry Mixing 
1 Omeprazole 20 20 20 20 20 20 
2 Mannitol 38 38 38 38 38 38 
3 Na2CO3 27 27 27 27 27 27 
4 Avicel PH102 16 16 16 16 16 16 
5 Aerosil 0.6 0.6 0.6 0.6 0.6 0.6 
Granulation 
6 Povidone 7 7 7 7 7 7 
7 IPA q.s q.s q.s q.s q.s q.s 
Sub coating 
8 HPMC 2.4 2.4 2.4 2.4 2.4 2.4 
9 IPA q.s q.s q.s q.s q.s q.s 
                                                            Enteric Coating 
10 HPMC P 12 16 _ _ _ _ 
11 Kollicoat MAE30DP _ _ 12 16 _ _ 
12 Eutragit NE30D  _ _ _ _ 12 16 
13 PEG 4 4 4 4 4 4 
14 Talc 0.6 0.6 0.6 0.6 0.6 0.6 
15 Water q.s q.s q.s q.s q.s q.s 
Tabletting Excepients And Lubrication 
16 Avicel PH200 68 64 68 64 68 64 
17 Iron Oxide Red 0.4 0.4 0.4 0.4 0.4 0.4 
18 Magnesiumstearate 2 2 2 2 2 2 
19 Talc 2 2 2 2 2 2 
 Total Weight 200 200 200 200 200 200 
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 Table No.14 Formulation Code of Domperidone Layer 
 
   PREPARATION OF OMEPRAZOLE ENTERIC COATED GRANULES: 
 Sifting of the granulation Material: 
o The Excipients were sifted by using mechanical sifter by using #40 screens. 
o API should be sifted separately. 
 Binder preparation: 
o Povidone is dissolved in sufficient quantity of Iso Propyl Alcohol to get a clear solution. 
 Mixing & granulation(RMG): 
o The excipients Mannitol and Avicel PH102 were loaded into RMG and Mixed for two 
minutes. 
o After dry mixing add Omeprazole (API) in to the RMG. Then mix for 15 minutes. 
o Aerosil was added to the dry mixed blend to absorb the moisture in the drug. 
o Then gently add binding agent in to the RMG and mix them thoroughly. By using 
impellor and chopper blades. 
o After granulation the material is transfer from RMG to the FBD for proper drying. 
S.No Ingredients 
F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
1 Domperidone 20 20 20 20 20 20 20 
2 HPMCK4M 32 48 _ _ 24 16 32 
3 HPMCK15M _ _ 32 48 8 32 16 
4 Lactose 72.5 56.5 72.5 56.5 72.5 56.5 56.5 
5 
Microcrystalline 
cellulose 
32 32 32 32 32 32 32 
6 
Magnesium 
stearate 
1.5 1.5 1.5 1.5 1.5 1.5 1.5 
7 Talc 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
8 Water q.s q.s q.s q.s q.s q.s q.s 
 Total Weight 160.0 160.0 160.0 160.0 160.0 160.0 160.0 
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 Drying(FBD): 
o The wet mass is dried by using Fluid Bed Dryer.  
 Sifting & milling: 
o The lumps which are formed in the process is separated by sifting. 
o The lumps were milled by using multi mill to reduce the size. 
  Coating solution preparation: 
o Talc and plastisizer are homogenized in water using homogenizer for 10 
min(excepient suspension) 
o Pour the excepient suspension slowly into the Enteric coating dispersion while stirring 
with conventional stirrer.(Spray suspension) 
o Pass the spray suspension through a 0.5mm sieve. 
 Enteric coating of Omeprazole Granules: 
o The enteric coating of granules was done by using Fluidized Bed Processer (FBP). 
o Before starting the coating process in FBP the spray gun pattern was adjusted in order 
to get uniform coating. 
o The base plate and mesh was stetted as per the size of the granules. i.e. A plate and 
100 # mesh. 
o After proper arrangement the equipment was given for pre warming in order to reach 
the bed temperature 28-30
º
C. 
o After attaining the bed temperature the granules were loaded into FBP. 
o Then the subcoating solution was sprayed with the help of peristaltic pump through 
the spray gun and dried. 
o After subcoating the enteric coating solution was sprayed with the help of peristaltic 
pump through the spray gun. 
o The coating process was continued until the coating solution gets finished. 
o Finally 10- 15 minutes drying has to be given for the coated granules. 
o The granules were collected from the FBP and weighed to check the process 
efficiency. 
o The main process parameters for the granules are as follows. 
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    Table No.15 Parameters of GPCG 
S.No In process Parameters of Coating 
1. Inlet temperature 40-45º C. 
2. Outlet temperature 28-30º C. 
3. Pump speed 1-4 rpm. 
4. Bed temperature 28-32º C. 
5. Atomization Pressure 0.3-0.7 bar 
 
 Pre lubrication of the granules: 
o The enteric coated granules were loaded in to the octagonal blender. 
o Then add previously weighed Avicel PH200 and mixed for 15 min. 
 Lubrication:  
o Pre-lubricated granules are lubricated with Magnesium stearate for 2 minutes 
 
PREPARATION OF DOMPERIDONE GRANULES: 
 Sifting of the granulation Material: 
o Domperidone, HPMCK4, HPMCK15, Avicel PH102 and Lactose  talc Magnesium 
Stearate were sifted by using mechanical sifter by using #40 screens. 
 Dry Mixing: 
o The excipients Lactose and Avicel PH102 and Polymer were loaded into RMG and 
Mixed for two minutes. 
o After dry mixing add Domperidone (API) in to the RMG. Then mix for 15 minutes. 
 Granulation: 
o Granulation is done by adding sufficient quantity of the water to the dry mixed blend 
continuously until the granules are formed. 
o After granulation the material is transfer from RMG to the FBD for proper drying. 
 Drying the granules by using : 
o The wet mass is dried by using Fluid Bed Dryer. 
 Sifting & milling: 
o The lumps which are formed in the process are separated by sifting. 
o The lumps were milled by using multi mill to reduce the size. 
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 Lubrication of the granules: 
o The granules were loaded in to the octagonal blender. 
o Then add previously weighed lubricating material Magnesium state and talc. 
o Then blend the material for 5 minutes. 
 
COMPRESSION OF BILAYER TABLETS: 
The blends of the two layers obtained are subjected to compression using 
CADMACH double sided compression machine. 
Compression involves two steps 
o Compression of the Domperidone layer with the desired parameters. 
o The Domperidone layer compression is followed by the compression of the 
Omeprazole layer. 
   Table No.16 Punches Specification 
S.No Punch Parameters 
1. Punch dimension 10.00 mm. 
2. Punch shape Circular, Flat punches. 
3. Upper punch Plain. 
4. Lower punch Plain. 
 
 
 
The following pre formulation studies were performed for the Omeprazole and 
Domperidone bi layer tablet formulations.  
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EVALUATION OF OMEPRAZOLE AND DOMPERIDONE BILAYER 
TABLETS
52,53,54 
7.7 Post-Compression Parameters: 
The tablets were evaluated for in process and finished product quality control 
tests  i.e. appearance, dimensions (diameter and thickness), weight variation, 
hardness,  friability, assay and drug content.  
7.7.1 Appearance: 
 The tablet should be free from cracks, depressions, pinholes etc. The colour 
and the polish of the tablet should be uniform on whole surface. The surface of the 
tablets should be smooth. 
7.7.2 Dimensions: 
 The dimensions of the tablets are thickness and diameter. The tablets should 
have uniform thickness and diameter. The manufacturer normally states these. 
Thickness and diameter of a tablet were measured using vernier calipers. These values 
were checked and used to adjust the initial stages of compression. 
7.7.3 Weight Variation test: 
Take 20 tablets and weighed individually. Calculate average weight and 
compare the individual tablet weight to the average. The tablet pass the U.S.P. test if 
not more that 2 tablets are outside the percentage limit and if no tablet differs by more 
than 2 times the percentage limit.  
  Table No.17 Limits of Weight Variation as per USP 
S.No. Average weight of tablet (X mg) 
Maximum % difference 
allowed 
1. 130 mg or less 10 
2. 130 mg to 324 mg 7.5 
3. More than 324 mg 5 
 
% Maximum positive deviation = (WH –A/ A) X 100 
% Minimum negative deviation = (WL - A / A) X 100    
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   Where,  
  WH = Highest weight in mg. 
  WL = Lowest weight in mg. 
  A = Average weight of tablet in mg. 
7.7.4 Hardness test: 
 Hardness (diametric crushing strength) is a force required to break a tablet 
across the diameter. The hardness of a tablet is an indication of its strength. The tablet 
should be stable to mechanical stress during handling and transportation. The degree 
of hardness varies with the different manufactures and with the different types of 
tablets.  
 7.7.5 Friability test:  
Friability is the loss of weight of tablet in the container/package, due to removal 
of fine particles from the surface. This in-process quality control test is performed to 
ensure the ability of tablets to withstand the shocks during processing, handling, 
transportation, and shipment. Roche friabilator was used to measure the friability of 
the tablets.  It is being rotated at a rate of 25 rpm. Take a sample of whole tablets 
corresponding as near as possible to 6.5gm and placed in the chamber of the 
friabilator.  In the friabilator, the tablets are exposed to rolling, resulting from free fall 
of tablets within the chamber of the friabilator.  After 100 rotations (4 minutes), the 
tablets are taken out from the friabilator and intact tablets are again weighed 
collectively.  Permitted friability limit is 1.0%. The percentage friability was 
measured by using the following formula 
 
                                       % F = {1-(W / Wo)} x 100 
                             Where,  
                                       %F = friability in percentage 
                                       Wo = Initial weight of tablet 
      W = Weight of tablets after revolution. 
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7.7.6 Content uniformity: 
A sample of 30 tablets are randomly seleced and 10 of them are individually 
assayed.9 of the 10 tablets must contain >85% and <115 of drug content. The tenth 
tablet must contain <75% and >125% of the labeled content.If these conditions are not 
met,the remaining 20 tablets are assayed individually and none must fall outside the 
85%-115% range. 
 
7.7.7 ASSAY PROCEDURE
63,64
:  
Chromatographic Condition 
Column   :        Phenomenex C18 (250x4.6 i.d., 5µm particle size) 
Flow Rate   :        1.0 ml/min  
UV Wave Length  :        295nm 
Injection Volume  :        10µ L 
Temperature    :         25˚C+2˚C 
Run Time   :        10 minutes. 
Preparation of Mobile phase: 
Prepare a filtered and degassed mixture of pH6.5 Ammonium acetate buffer: 
methanol: acetonitrile in the ratio of 40:30:30 v/v/v and pH was adjusted to 7.44+0.02 
with acetic acid/ammonia. 
Preparation of Solutions: 
Standard preparation: 
Weigh accurately and transfer 20.0 mg of Omeprazole and 20.0 mg of 
Domperidone in to a 100 mL volumetric flask, dissolved in and diluted to mark with 
methanol. 1 ml of this solution was further diluted to 50 mL  with mobile phase. 
Sample preparation: 
 Weighed and finely powdered 20 tablet and transfer a portion of the resulting 
powder equal to the weight of respective tablet to 100 mL volumetric flask. Add 60 
mL of methanol and sonicated for 15 min with occasional shaking and made the 
volume up to volume with methanol.  Filtered the solution through 0.45µ filter. 
Pipette out 2.0 mL of the filtered solution and diluted to 100 mL with Mobile phase.  
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Procedure: 
Separately inject equal volume of Mobile phase (blank), standard preparation  
and test preparation, record the chromatograms, and measure the areas for the 
Omeprazole and Domperidone. Calculate the quantity of Omeprazole and 
Domperidone. 
CALCULATION: 
% Of Omeprazole: 
  
  
   
  
   
   
 
  
   
   
  
   
 
   
           
 
   
   
   
  
 
       Where, 
    SA = peak area due to Omeprazole in standard preparation. 
    TA  = Peak area due to Omeprazole in sample preparation 
   SW  = Weight of Omeprazole working standard, in mg. 
    P     = Purity of Omeprazole working standard. 
   LA = Labeled amount of Omeprazole, in mg. 
            TW    =  weight of sample taken in mg 
     Ave. wt.    = Average weight of tablet. 
   
% of DOMPERIDONE: 
 
  
  
   
  
   
   
 
  
  
   
  
  
 
   
          
 
   
   
   
   
 
    Where, 
 SA =   peak area due to Domperidone in standard preparation. 
 TA =    Peak area due to Domperidone in sample preparation 
 WS =   Weight of Domperidone working standard, in mg. 
 P       =   Purity of Domperidone working standard. 
 LA    =   Labeled amount of Domperidone, in mg. 
          TW =   weight of sample taken in mg 
     Ave. wt.   =   Average weight of tablet. 
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7.8 GASTRIC RESISTANT FOR OMEPRAZOLE
56,63,64
: 
Dissolution Condition 
Medium  : 0.1 M HCl 750mL 
Apparatus  : USP Type-2 (paddle) 
Speed   : 100 RPM 
Time interval  : 2 hrs 
Temperature  : 37+ 0.5
˚ 
C 
Chromatographic Condition 
Column  :     Phenomenex C18 (250x4.6 i.d., 5µ m particle size) 
Flow Rate  : 1.0 ml/min  
UV Wave Length :      301nm 
Injection Volume : 20µ L 
Temperature  :       25
˚
C+2
˚
C 
Run Time  : 10 minutes. 
Preparation of Mobile phase: 
 Prepare a filtered and degassed mixture of pH6.5 Ammonium acetate buffer: 
methanol: acetonitrile in the ratio of 40:30:30 v/v/v and ph was adjusted to 7.44+0.02 
with acetic acid/ammonia. 
Preparation of 0.1M Hydrochloric acid( pH 1.2) : 
Measure 8.5 ml of Hydrochloric acid is mixed well and dissolved in 1000 ml 
of water to produce required 0.1M Hydrochloric acid. 
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Standard Preparation: 
Weigh accurately 20mg of omeprazole into dry, stoppered test-tube, add 20.0 
ml of 0.1 M sodium hydroxide, shake vigorously for 5 minutes and dilute 1.0 ml of 
the solution with the mobile phase to produce 50.0 ml. 
Sample Preparation: 
 Tablets were placed in each dissolution baskets which contains 750 ml of 0.1 
N HCl. Then run the dissolutions apparatus as per the above mentioned dissolution 
parameters. After 2 hours drain the solution without losing of any granules. Transfer 
them to a 100ml volumetric flask, add 20ml of 0.1M NaOH, and mix with the aid of 
ultrasound. Dilute to volume with 0.1M NaOH, centrifuge about 15ml for 15min and 
dilute 5ml of the clear supernatanant liquid to 50ml with mobile phase.  
 Then the value was subtracted from the initial assay value. Then we can get 
the % drug released from the tablet. 
Procedure: 
Separately inject equal volume of Mobile phase (blank), standard preparation  
and test preparation, record the chromatograms, and measure the areas for  
Omeprazole.  
Calculation: 
% OF OMEPRAZOLE: 
  
  
   
  
  
   
 
  
   
   
  
   
 
  
           
 
   
   
   
  
 
           Where, 
  SA = peak area due to Omeprazole in standard preparation. 
  TA = Peak area due to Omeprazole in sample preparation 
  SW= Weight of Omeprazole working standard, in mg. 
  P    = Purity of Omeprazole working standard. 
  LA = Labeled amount of Omeprazole, in mg. 
                    WT = weight of sample taken in mg 
    Ave. wt. = Average weight of tablet 
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 7.9 PROCEDURE FOR DISSOLUTION TESTING
56,57,63,64
: 
Dissolution Condition 
Medium  : pH 1.2 HCl 750 mL, pH6.8 phosphate buffer 1000mL 
Apparatus  : USP Type-2 (paddle) 
Speed   : 100 RPM 
Temperature  : 37+ 0.5
° 
C 
Chromatographic Condition 
Column  : Phenomenex C18 (250x4.6 i.d., 5µ m particle size) 
Flow Rate  : 1.0 ml/min  
UV Wave Length       :          295nm 
Injection Volume : 20µ L 
Temperature   : 25
˚
C+2˚C 
Run Time  : 10 minutes. 
Dissolution Medium Preparation: 
Preparation of 0.1 N Hydrochloric Acid (pH 1.2): 
Measure 8.5 ml of concentrate hydrochloric acid was taken and diluted with 
distilled water up to 1000 ml. 
Preparation of pH6.8 Phosphate buffer: 
After 2 hours of operation in 0.1 N hydrochloric acid add to the fluid in the 
vessel 250 mL of 0.20 M tribasic sodium phosphate that has been equilibrated to 37 ± 
0.5 . Adjust, if necessary, with 2 N hydrochloric acid or 2 N sodium hydroxide to a 
pH of 6.8 ± 0.05. 
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Preparation of Mobile phase: 
Prepare a filtered and degassed mixture of pH6.5 Ammonium acetate buffer: 
methanol: acetonitrile in the ratio of 40:30:30 v/v/v and ph was adjusted to 7.44+0.02 
with acetic acid/ammonia. 
Preparation of Solutions: 
Standard Preparation: 
Weigh accurately and transfer 20.0 mg of Omeprazole and 20.0 mg of 
Dmperidone in to a 100 mL volumetric flask, add sufficient amount of dissolution 
medium, sonicate to dissolve and make up to volume with dissolution medium.From 
this 1ml is taken and is diluted to 100ml and inject the solution directly in HPLC. 
 Sample Preparation: 
Acid Stage: 
Place one tablet in each of six vessels containing 750 mL of pH1.2 HCl 
medium that has been equilibrated to 37˚C+ 0.5˚C. Take care to exclude air bubbles 
from the surface of the tablet, and immediately operate the apparatus with prescribed 
instrument condition for 2hrs. In every 30 min interval of dissolution, withdraw 5mL 
of sample solution from a zone midway between the surface of dissolution medium 
and the top of the  rotating paddle, not less than 1 cm from the vessel wall and filter 
through 0.45µ filter, and inject the solution directly in HPLC. 
Buffer Stage: 
After 2 hours of operation in 0.1 N hydrochloric acid add to the fluid in the 
vessel 250 mL of 0.20 M tribasic sodium phosphate that has been equilibrated to 37 ± 
0.5 . Adjust, if necessary, with 2 N hydrochloric acid or 2 N sodium hydroxide to a 
pH of 6.8 ± 0.05. Continue to operate the apparatus for 10hrs. For every 10min time 
interval of dissolution, withdraw 5mL of sample solution for omeprazole drug release 
up to 1hr and there after for every 1hr from a zone midway between the surface of 
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dissolution medium and the top of the  rotating paddle, not less than 1 cm from the 
vessel wall and filter through 0.45µ filter, and inject the solution directly in HPLC. 
Procedure: 
Separately inject equal volume of Mobile phase, Blank (Dissolution medium) 
standard ( Five replicate injection) and test preparation, record the chromatograms, 
and measure the areas for the Omeprazole and Domperidone. Calculate the quantity 
of Omeprazole and Domperidone. 
CALCULATION: 
% of Omeprazole: 
  
  
 
  
   
 
 
   
 
    
  
 
  
 
 
 
   
     
     Where, 
 SA    = peak area due to Omeprazole in standard preparation. 
 TA   = Peak area due to Omeprazole in sample preparation 
 SW   = Weight of Omeprazole working standard, in mg. 
 P      = Purity of Omeprazole working standard. 
 LA   = Labeled amount of Omeprazole, in mg. 
 
  % of Domperidone: 
           
  
  
 
  
   
 
 
   
 
    
  
 
  
 
 
 
   
     
         Where, 
  TA    = Peak area due to Domperidone in sample preparation 
             SA    = peak area due to Domperidone in standard preparation. 
            SW    = Weight of Domperidone working standard, in mg. 
  P       = Purity of Domperidone working standard. 
            LA     = Labeled amount of Domperidone, in mg. 
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 7.10 RELEASE KINETICS
57,58
: 
7.10.1 Dissolution Profile Modelling: 
Over recent years, the in vitro dissolution has been recognized as an important 
tool in drug development. In vitro dissolution has been recognized as an important 
parameter in quality control and under certain conditions, it can be used as a surrogate 
for the assessment of bio-equivalence or prediction of bioequivalence. Guidance 
recommends USP dissolution equipment is satisfactory. However modification of 
current dissolution equipment or completely new designs may be needed to 
accommodate new release mechanisms. Generally, methods of agitation, changing the 
media, and holding the dosage form in the media without interfering with the release 
mechanism of dosage form as well as the physical chemical properties of the drug 
will enable development of accurate dissolution tests. 
An appropriate drug release test is required to characterize the drug product 
and ensure batch-to-batch re-reducibility and consistent pharmacological/biological 
activity and to evaluate scale up and post approval changes such as manufacturing 
site changes, component and composition changes. The release of the drug from a 
sustained release formulation is controlled by various factors through different 
mechanisms such as diffusion, erosion or osmosis. Several mathematical models are 
proposed by many researchers to describe the drug release profiles from various 
systems. In order to characterize the kinetics of drug release from dosage forms 
several model dependent methods are reported by various researchers. The model 
dependent methods all rely upon a curve fitting procedure. Different mathematical 
functions have been used to model the observed data. Both the linear and non-linear 
models are being used in practice for dissolution modeling. Linear models include 
Zero order, Higuchi, Hixson-Crowell, where as the nonlinear models include first 
order, Weibull, Korsmeyer-Peppas, Logistc etc. 
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 7.10.2 Mathematical models (Release Kinetics) : 
To study the release kinetics of the drug from the reservoir tablets, the release data 
were fitted to the following equations: 
a) Zero order equation 
                                               Qt   = k0.t (1) 
Where Qt is the percentage of drug released at time t and k0 is the release rate constant; 
the zero order rate Eq. (1) describes the systems where the drug release rate is 
independent of its concentration.  
b) First order equation 
                         In (100-Qt)  =  In 100  – k1.t                                                    (2) 
Where k1 is the release rate constant; 
The first order Eq. (2) describes the release from system where release rate is 
concentration dependent. 
The release of drug from matrix based pharmaceutical systems has been given 
great interest over the last 20 years. These devices have been extensively used for the 
delivery of drugs over an extended period of time. Significant experimental and 
theoretical work has been performed to accurately model drug transport and reveal the 
mechanisms of drug release from these systems. Basically three main mathematical 
approaches were used for the drug release through matrix systems: Higuchi's model, 
Korsmeyer and Peppas model and Hixson Crowell cube root law.  
c)  Higuchi's Model 
                                                         Qt  =  kH.t
1/2                                                                                                                                
(3) 
Where kH is the Higuchi release rate constant; 
Higuchi described the release of drugs from insoluble matrix as a square root of 
time dependent process based on Fickian diffusion Eq. (3). According to this model 
the fraction of drug released is proportional to the square root of time. The basic assumption 
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for the derivation of Eq. (1) is that the initial concentration of the drug in the system, C0, is 
much higher than drug solubility, Cs and diffusion is the sole mechanism of drug 
release. The Higuchi's model basically gives an idea of only the mechanism of diffusion 
through a matrix based system which is generally for the water soluble drugs. When the 
mechanism of diffusion as well as erosion is involved another model came into picture 
which gives an idea of the erosion mechanism also involved.  
d) Hixson-Crowell model 
                        (100-Qt)
1/3
 = 100
l/3 – kHC.t                                                                  (4) 
Where kHC is the Hixson-Crowell rate constant. 
Hixson-Crowell model (Equation 4) describes the release of drugs from an 
insoluble matrix through mainly erosion. (Where there is a change in surface area and 
diameter of particles or tablets.) 
e) Korsmeyer - Peppas Model (Mechanism of Drug Release) 
 To evaluate the mechanism of drug release, the Korsmeyer-Peppas model was applied: 
                                                 Qt/Q∞ = kKP. t
n
                                                              (5) 
Where Qt/Q∞ is the fraction of drug released at time t, kKP a constant 
compromising the structural and geometric characteristics of the device, and n, the 
release exponent, which is indicative of the mechanism of drug release. 
                               Table No.18 Mechanism of drug release 
Diffusion Exponent(n) 
 
Release 
 0.45 ≤ n 
 
Fickian diffusion 
 0.45<n≤0.89 
 
Anomalous(Non-Fickian) diffusion 
n = 0.89 Case II transport (swelling-controlled drug release) 
n > 0.89 
 
Super Case II transport 
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The mechanism of release can be indicated according to Korsmeyer where n is the 
release exponent, indicative of mechanism of drug release. Fickian  diffusional release and 
a case II relaxational release (swelling-controlled drug release) are the limits of this 
phenomenon. Fickian diffusional release occurs by the usual molecular diffusion of the 
drug due to a chemical potential gradient. Case-11 relaxational release is the drug 
transport mechanism associated with stresses and state-transition in hydrophilic glassy 
polymers which swell in water or biological fluids. This term also includes polymer 
disentanglement and erosion. The rate controlling step in Case II transport kinetics is the 
swelling which occurs at the internal moving boundary. Anomalous transport kinetics 
indicates a combined mechanism of pure diffusion and Case II transport. Super Case II 
transport mechanism could result from increased plasticization at the relaxing boundary (gel 
layer). 
7.10.3 Determination of kinetics of release from dosage form: 
The mathematical modelling of drug release is of great importance in pharmaceutical 
science and engineering because the idealized but key transport mechanisms can be 
studied in the mathematical model and the model itself can be used to predict the effects of 
the composition and geometry on drug release profiles, which is very helpful to the design 
of new drug delivery system. The mechanism study of drug release via a swellable and 
dissoluble hydrophilic polymer matrix is not as extensive as for purely diffusion, swelling 
or polymer dissolution controlled drug release systems since all these processes are coupled, 
thus making the models more intricate and difficult to solve. 
Generally, in swelling controlled matrix systems of controlled formulations, there are 
two major factors which control the rate of release of the drug from the matrix. One is the rate 
of aqueous medium infiltration into the matrix followed by a relaxation process 
(hydration, gelation or swelling) and the other is the rate of erosion of the matrix. As a 
result of these simultaneous processes, two fronts are evident, a swelling front (glassy 
polymer/gel interface) and an eroding front (gel/medium interface). The distance between the 
two fronts (diffusion layer thickness) depends on the relative rates at which the 
swelling and eroding fronts move in relation to each other. There have been several 
mathematical models proposed to describe the system. The mathematical approaches 
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most frequently used to describe the mechanism of drug release are those of Higuchi and 
Hixson Crowell cube root law. 
The selection of particular model for release is based on regression coefficient of 
release profile obtained from its slope. The regression value (r
2
) approaching towards 1 
shows best fit for particular model. Hence the model for which release profile shows the 
regression coefficient value close to 1 was chosen for determination of release of drug 
from dosage form. 
 
7.11 SIMILARITY FACTOR AND DISSIMILARITY FACTOR          
CALCULATION
59,60 
The similarity factor (f2) was defined by CDER, FDA, and EMEA as the 
―logarithmic reciprocal square root transformation of one plus the mean squared 
difference in percent dissolved between the test and reference release profiles‖. 
Dissimilarity or difference factor (f1) describes the relative error between two 
dissolution profiles. It approximates the percent error between the curves. The percent 
error is zero when the test and reference release profiles are identical and increases 
proportionally with the dissimilarity between the two profiles.  
There are several methods for dissolution profile comparison. f2 is the 
simplest among those methods. Moore & Flanner proposed a model independent 
mathematical approach to compare the dissolution profile using two factors f1 & f2.  
 f1 = { [  t=1 
nRt – Tt  ] / [  t=1 
n
 Rt ] } . 100 
 f2 = 50. log { [1 + ( 1/n)  t=1 
n
 (Rt - Tt ) 
2
 ] 
–0.5 
. 100} 
Where 'Rt' and ‗Tt' are the cumulative percentage dissolved at each of the 
selected n time point of the reference & test product respectively. The factor f1 is 
proportional to the average difference between the two profiles, where as factor f2 is 
inversely proportional to the averaged squared difference between the two profiles, 
with emphasis on the larger difference among all the time points. The similarity factor 
f2 and its significance is shown in the following table. 
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  Table No.19 Similarity factor f2 and its significance 
S. No. 
Similarity factor 
(f2) 
Significance 
1. <50 Test and reference profiles are dissimilar. 
2. 50 -100 Test and reference profiles are similar. 
3. 100 Test and reference profiles are identical. 
4. >100 The equation yields a negative value. 
 
7.12 STABILITY STUDY
61,64
 
Stability studies are an integral part of the drug development program & are 
one of the most important areas in the registration of Pharma products. The purpose 
of stability testing is to provide evidence on how the quality of a drug substance or 
drug product varies with time under the influence of a variety of environmental 
factors such as temperature, humidity & light & enables recommended storage 
conditions, re-test periods and self half lives to be established. Stability assessment 
starts with studies on the substance to determine degradation products degradation 
pathway. In these types of studies the product is analyzed at intervals for various 
parameters which may include assay of active ingredient, measurement of known 
degradation products, hardness, dissolution time, appearance, etc., Omeprazole and 
Domperidone Bilayer tablets were packed in HDPE containers and  evaluated for 
accelerated stability studies at 40ºC/75% RH conditions. 
Storage conditions: 40±2
º
C/75±5%RH. 
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   8. RESULTS AND DISCUSSION 
 8.1 Organoleptic Properties:  
          Table No.20  Organoleptic Properties for Omeprazole 
Test Specification / limits Observations 
Colour White or almost white powder White or almost white powder 
Taste Bitter Bitter 
Odour Characteristic odour  Characteristic odour 
 
                                Table No.21 Organoleptic Properties for Domperidone 
Test Specification / limits Observations 
Colour White or almost white powder White or almost white powder 
Taste Bitter Bitter 
Odour Characteristic Odour Characteristic Odour 
 
 
 8.2 Angle Of Repose: 
        Table No.22 Angle of repose for Omeprazole 
S. No. Material Angle of repose Average angle of repose 
1. 
Omeprazole 
38
.
37
°
 
38
.
56
°
±0.54 2. 39
.
17
°
 
3. 38
.
14
°
 
 
        Table No.23 Angle of repose for Domperidone 
 
 
 
S. No. Material Angle of repose Average angle of repose 
1. 
Domperidone 
38
.
34
°
 
38
.
66º±0.52 2. 39
.
27
°
 
3. 38.38
°
 
Chapter-8                                                                                   Results and Discussion 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode                   77 
 8.3 Determination of Bulk density and Tapped density: 
                 Table No.24 Bulk Density and Tapped Density for Omeprazole 
 
    Table No.25 Bulk Density and Tapped Density for Domperidone 
S.No. Material 
Bulk 
Density 
(gm / ml ) 
Average 
Bulk 
Density 
(gm / ml) 
Tapped 
Density 
(gm / ml) 
Average 
Tapped 
Density 
(gm / ml) 
1 
Domperidone 
0.346 
0.346± 
0.01 
 
0.526 0.521± 
0.01 
 
 
2. 0.344 0.516 
3. 0.348 0.523 
 
 
8.4 Powder Compressibility and Hausner ratio 
                      Table No.26 Compressibility Index and Hausner ratio 
Materials Compressibility index Hausner ratio 
Omeprazole 32.64 1.48 
Domperidone 33.58 1.51 
  
  
 
S.No. Material 
Bulk 
Density 
(gm / ml ) 
Average 
Bulk 
Density 
(gm / ml) 
Tapped 
Density 
(gm / ml) 
Average 
Tapped 
Density 
(gm /cc) 
1 
Omeprazole 
 
0.364 0.359± 
0.01 
 
0.531 0.533± 
0.01 
 
2. 0.358 0.536 
3 0.357 0.532 
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 The organoleptic characters of the bulk products namely Omeprazole and 
Domperidone comply with monograph specifications of USP and IP respectively. The 
flow properties, poured density, tapped density, compressibility index, Hausner ratio 
also complies with the above said specifications revealing that the former exhibits 
poor flow and the latter exhibits very poor flow with the exception that Hausner ratio 
value of metoprolol implies very poor flow. 
 
 8.5 LOD studies: 
 The Loss on drying for Omeprazole was 0.12% and for Domperidone it was     
0.17%. It complies with in the limit. 
8.6 Solubility: 
  The following table illustrates the results of solubility studies 
      Table No.27 Solubility of Omeprazole  
Quantity of 
Metoprolol 
Succinate 
Quantity of solvents Inference 
100 mg 
100 mg 
100 mg 
100 ml of water 
100 ml of 95 % ethanol 
100 ml methanol 
Slightly soluble 
Freely soluble 
Freely Soluble 
  
 Table No.28 Solubility of Domperidone 
Quantity of 
Ramipril 
Quantity of solvents Inference 
 
100 mg 
100 mg 
100 mg 
100 mg 
 
 
100 ml of water 
100 ml of 95 % ethanol 
100 ml of methanol 
100ml of dimethylformamide 
 
Very slightly soluble 
Sparingly soluble 
Slightly Soluble 
Sprangly soluble 
 
Chapter-8                                                                                   Results and Discussion 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode                   79 
The solubility studies of Domperidone reveals that drug belongs to  BCS class 
II. These facts imply the necessity to choose a high viscous grade hydrophilic  
polymer to retard the drug release of Domperidone for formulating as a extended 
release layer. 
 
8.7 Analytical method development for Omeprazole and Domperidone 
Absorption Maxima Scan of Omeprazole and Domperidone: 
 
                          Fig No.4  λmax Scan of Omeprazole and Domperidone 
A spectrum of the working standards is obtained by scanning from 200-400nm 
against the reagent blank to fix absorption maxima. The λmax is found to be 295.0nm. 
Hence standard curve and dissolution testings  are being carried out at the same 
wavelength. 
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 8.7.1 Calibration curve for Omeprazole 
The standard calibration curve is plotted by preparing various concentrations 
of the Omeprazole in phosphate buffer of pH 6.8. 
   Table No.29  Preparation of Standard graph for Omeprazole 
 
 
 
 
 
 
 
 
 
 
 
 
Graph No.1 Standard curve for Omeprazole 
 
 
S.No Conc.(µg/mL) Peak Area 
1 0 0 
2 2 602545 
3 4 1235841 
4 6 1878547 
5 8 2469874 
6 10 3048752 
7 12 3654781 
R² = 0.999
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
4000000
0 2 4 6 8 10 12 14
Concentration(µg/mL)
P
ea
k
 A
re
a
Standard Curve for Omeprazole
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8.7.2 Calibration curve for Domperidone 
 The standard calibration curve is plotted by preparing various concentrations 
of Domperidone in phosphate buffer of pH 6.8. 
Table No.30 Preparation of Standard graph for Domperidone 
 
 
 
 
 
 
 
 
 
Graph No.2 Standard curve for Domperidone 
 
 
S.No Conc.(µg/mL) Peak Area 
1 0 0 
2 2 458421 
3 4 854782 
4 6 1287425 
5 8 1687450 
6 10 2085478 
7 12 2458745 
R² = 0.9993
0
500000
1000000
1500000
2000000
2500000
3000000
0 2 4 6 8 10 12 14
Standard Curve for Domperidone
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8.8 Drug-Excipient compatibility study at 40° C / 75 % RH 
The various drug excipient mixtures are subjected to compatibility studies by 
keeping the blends under accelerated conditions, 40° C / 75 % RH for a period of 4 
weeks.  After 4 Weeks of study physical appearance of these compositions were made 
and compared with the initial observations. These observations are recorded in Table
   
Table No.31 Excipients compatibility studies for Omeprazole 
S.No Composition 
Ratio 
Physical Appearance 
Initial 
1
st
 
week 
2
nd
 
week 
3
rd
 
week 
4
th
 
week 
1. Omeprazole 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
2. 
Omeprazole                 
+ 
Mannitol 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
3 
Omeprazole 
+ 
NaHCO3 
1:0.5 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
4. 
Omeprazole 
+ 
Povidone 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
5. 
Omeprazole 
+ 
Avicel 
PH102 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
6 
Omeprazole 
+ 
Aerosil 
1:0.25 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
7. 
Omeprazole 
+ 
Mg. stearate 
1:0.5 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
8. 
Omeprazole 
+ 
Talc 
1:0.5 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
 
* NCC – No characteristic change 
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     Table No.32 Excipients compatibility studies for Domperidone 
S.No Composition 
Ratio 
Physical Appearance 
Initial 
1
st
 
week 
2
nd
 
week 
3
rd
 
week 
4
th
 
week 
1. Domperidone 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
2. 
Domperidone 
+ 
HPMC K4 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
3 
Domperidone 
+ 
HPMC K15 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
4. 
Domperidone 
+ 
Lactose 
monohydrate 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
5. 
Domperidone 
+ 
Avicel pH101 
1:1 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
6. 
Domperidone 
+ 
Magnesium 
stearate 
1:0.5 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
7. 
Domperidone 
+ 
Talc 
1:0.5 
A white or almost 
white crystalline 
powder 
NCC NCC NCC NCC 
 
* NCC – No characteristic change 
After the storage, the samples were observed physically for liquefaction, 
caking and discoloration. It shows that there is no significant difference in the colour 
and appearance of the mixtures after 4 weeks at 40°C / 75% RH. Hence the selected 
excipients are likely to be suitable for the preparation of the bilayer tablets. 
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8.9 PARTICLE SIZE ANALYSIS OF API 
Table No.33 Size Analysis of Omeprazole & Domperidone 
Sieve 
number 
Arthimatic 
mean size 
opening(µm) 
(A) 
Omeprazole Domperidone 
% weight 
retained(B) 
Weight 
size(A*B) 
% weight 
retained(B) 
Weight 
size(A*B) 
50 300 1.2 360 0.7 210 
70 212 7.4 4473.2 12.6 2671.2 
100 150 11.7 1755 20.7 3105 
150 125 21.6 1262.5 13.7 1712.5 
170 90 18.6 1476 17.9 1611 
200 75 19.6 1470 10.7 802.5 
Pan - 19.3 0 23.4 0 
Total  99.4 9527.8 99.7 10112.2 
                                 
  Average Particle size of Omeprazole=9527.8/99.4=95.8531µm 
           
   Average Particle size of Domperidone=10112.2/99.7=101.42µm 
  
 Particles in the above size ranges are found to pose no serious problems like 
charge development. Therefore it was decided to use the API as it can be used without 
any further processing (like milling to decrease the particle size or adsorption or 
removal of fine to decrease cohesive forces). 
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8.10  DRUG –POLYMER COMPATIBILITY STUDIES BY FTIR: 
The FTIR spectra of Omeprazole, and the combination of drug and excepients   
shows no significant interaction between drug and excepients. 
 
    
   Fig No.5 FTIR Spectra of Omeprazole Drug. 
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Table No.34 Interpretation values of Omeprazole Spectra 
                
IR spectral analysis of Omeprazole showed the peaks at wave numbers of 
3457.2 (N-H Asymmetric stretching), 2978.1 (CH3 Alkyl Stretching)1575.5 (C=C 
Stretching), 1509.5,1462.3 (C-C  Aromatic stretching), 1306.8(S=O Stretching), 
1261.8 (C-N Stretching), 1157.2 (C-O Stretching) confirming the purity of drug with 
standard respectively. 
 
                       
 
 
S.No Functional Group 
Assessment of peak(cm
-1
) 
of pure drug 
Range of Groups 
1. N-H Stretching 3457.2 3509-3450 
2. CH3- Alkyl Stretching 2978.1 3032-2953 
3. C=C Stretching 1575.5 1590-1560 
4. C-C Aromatic stretching 1509.5 1500-1510 
5. S=O Stretching 1306.8 1300-1350 
6. C-N Stretching 1261.8 1350-1280 
7 C-O  Stretching 1157.2 1160-1060 
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Fig No.6 FTIR Spectra Omeprazole Optimised Formulation. 
 
In the physical mixture of Omeprazole with excepients the major peaks of 
Omeprazole  are present. However, additional peaks were observed in physical 
mixtures which could be due to presence of excepients and indicated that there was no 
chemical interaction between Omeprazole and other excipients. 
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FTIR absorption spectra of Domperidone and all the polymer used like HPMC 
K4M, HPMC K15M shows no significant interaction between drug and polymers. 
The graphs obtained were shown in the following FTIR spectras . 
 
   Fig No.7 FTIR Spectra of Domperidone. 
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Table No.35 Interpretation values of Domperidone Spectra 
 
S.No Group Assigned 
Assessment of 
peak(cm
-1
) of pure 
drug 
Range of groups 
1. 
C-H Stretching Aromatic 
Ring 
3021.5 3030-3020 
2. C=O Stretching 1835.4 1850-1790 
3. N-H Bending 1623.0 1650-1590 
4 C=C  Stretching 1485.7 1470-1520 
5. C-H Bending 1384.9 1380-1390 
6. C-N Stretching 1272.8 1340-1250 
 
 
IR spectral analysis of Domperidone showed the peaks at wave numbers of 
3021.5 (C-H Stretching Aromatic Ring )  1835.4(C=O Stretching ) 1623.0(N-H 
Bending) 1485.7(C=C Stretching) 1384.9 (C-H Bending) 1272.8(C-N Stretching)  
confirming the purity of drug with standard respectively. 
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  Fig No.8 FTIR Spectra of Domperidone+HPMC K4 
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Fig No.8 FTIR Fig No.9 FTIR.Spectra of Domperidone + HPMC K15 
 
In the physical mixture of Domperidone with Hydroxy propyl methyl cellulose 
K4M and K15M  the major peaks of Domperidone  are present. However, additional 
peaks were absorbed in physical mixtures which could be due to presence of polymers 
and indicated that there was no chemical interaction between Domperidone and other 
excipients. 
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8.11Characterization of tablets 
 8.11.1 Pre-compression parameters 
 The derived properties of the formulated blends are studied at ambient 
conditions using standard protocols and the data is tabulated in the tables. 
 
  Table No.36 Pre-compression parameters of Omeprazole batches F1 to F6 
Batch 
Derived Properties Flow Properties 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
Loss on 
Drying 
Angle of 
Repose (º) 
Compress
ability  
Index 
Hausner’s 
Ratio 
F1 
0.34±0.002 0.39±0.006 1.34±0.07 28.33±0.31 13.52±0.86 1.15±0.011 
F2 
0.34±0.003 0.39±0.001 1.34±0.07 29.05±0.13 11.28±0.42 1.12±0.005 
F3 0.35±0.01 0.38±0.003 1.47±0.10 29.15±0.20 8.16±3.44 1.08±0.041 
F4 
0.33±0.008 0.37±0.005 1.52±0.05 31.83±0.22 10.84±3.58 1.12±0.045 
F5 
0.35±0.010 0.40±0.003 1.40±0.16 28.41±0.26 12.87±2.96 1.14±0.039 
F6 
0.32±0.006 0.35±0.004 1.36±0.08 27.72±0.13 9.62±1.10 1.10±0.013 
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Table.No.37 Pre-compression parameters of Domperidone batches F1 to F7 
Batch 
Derived Properties Flow Properties 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
Loss on 
Drying 
Angle of 
Repose (º) 
Compressi
bility     
Index 
Hausner’s 
Ratio 
F1 0.34±0.005 0.39±0.004 1.47±0.07 31.6±0.34 10.81±0.48 1.12±0.006 
F2 
0.36±0.004 0.41±0.002 1.38±0.14 30.7±0.13 12.42±1.58 1.14±0.020 
F3 
0.37±0.004 0.41±0.004 1.43±0.05 32.71±0.12 10.34±1.67 1.11±0.020 
F4 
0.37±0.006 0.44±0.008 1.51±0.12 31.63±0.36 15.87±2.31 1.18±0.032 
F5 0.38±0.005 0.45±0.005 1.46±0.08 29.52±0.28 14.11±1.39 1.16±0.018 
F6 
0.39±0.009 0.46±0.003 1.38±0.13 27.81±0.25 15.12±1.81 1.17±0.025 
F7 0.35±0.005 0.38±0.001 1.42±0.06 28.14±0.14 9.32±1.19 1.10±0.014 
 
 
The angle of repose (Ө) is a characteristic of the internal  friction or cohesion 
of the particles and  the value of the angle of repose will be high if the powder is 
cohesive and low if the powder is non cohesive.  
The range of angle of repose for all the Omeprazole formulations is 27.7° to 
31.83°which indicates that flow of the granules ranges from excellent to good. 
Formulations  F4 showed angle of repose above 30°, indicating that the formulation 
have good flow properties and the rest of the formulations showed excellent flow 
properties. 
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The range of angle of repose for all Domperidone the formulations is 27.81° to 
32.71°which indicates that flow of the granules ranges from excellent to good. 
Formulations  F5, F6  and F7 showed angle of repose in between 25° and 30°, 
indicating that these formulations have excellent flow properties and the rest of the 
formulations showed good flow properties. 
Powders showing Carr’s index (%) up to 21 are considered of acceptable flow 
properties
101.The range of Carr’s index for the Omeprazole formulations is 8.16% to 
13.52% which indicates that the granules have excellent to fair flow. The Carr’s index 
for the optimized formulation, F6 is 9.62% 
 Powders showing Carr’s index (%) up to 21 are considered of acceptable flow 
properties. The range of Carr’s index for the Domperidone formulations is 9.32% to 
15.87% which indicates that the granules have excellent to fair flow. The Carr’s index 
for the optimized formulation, F7 is 9.32%. 
In addition to Carr’s index, Hausner found that the ratio DBmax/DBmin was 
related to the inter particle friction, so, he showed that powders with low inter particle 
friction, had ratios of approximately 1.25 indicating good flow. The range of 
Hausner’s ratio for all the Omeprazole  formulations is 1.08 to 1.15. The optimized 
formulation, F6 has Hausner’s ratio of 1.10 indicating that the the flow is excellent 
 In addition to Carr’s index, Hausner found that the ratio DBmax/DBmin was 
related to the inter particle friction, so, he showed that powders with low inter particle 
friction, had ratios of approximately 1.25 indicating good flow. The range of 
Hausner’s ratio for all the Domperidone formulations is 1.10 to 1.18. The optimized 
formulation, F7 has Hausner’s ratio of 1.10 indicating that the the flow is excellent 
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8.11.2 Post compression parameters: 
Table No.38 Post compression Parameters of Omeprazole and Domperidone 
Bilayer tablet 
 
All the formulations are tested for the post compression parameters like 
hardness, friability, thickness and weight variation. 
The hardness of all the formulated tablets are maintained at a constant value of 
8 kg / cm
2 
.Since the quantity of drug varies in both the layers weight variation is also 
an important parameter which needs to be checked. The weight variation for all the 
formulations is in par with the criteria mentioned in the USP. 
The thickness of the tablets ranges from 2.93 to 3.03 and are within the limits 
of the standard deviation. Uniform distribution of the drug is another key aspect 
which directly relates to the efficacy of the tablet. The range of the content uniformity 
for Omeprazole varies from 97.3 % to 101.67% and for Domperidone aries from 
97.76% to 98.8%. All the values are in par with the USP criteria. 
 
 
 
Batch 
Hardness 
(kg/cm
2
) 
Thickness 
( mm) 
Weight 
variation 
( mg ) 
Friability 
( % ) 
Content uniformity 
( % ) 
OME DOM 
F1 8.25±0.05 2.97±0.04 359.1±1.9 0.43±0.02 97.77±0.38 98.73±0.32 
F2 8.28±0.03 3.02±0.01 358.7±1.5 0.53±0.03 98.58±0.19 97.96±0.35 
F3 8.25±0.04 3.03±0.01 359.0±1.6 0.59±0.04 101.67±0.6 98.50±0.62 
F4 8.27±0.03 3.02±0.07 361.8±3.1 0.48±0.03 98.47±0.68 98.60±0.62 
F5 8.26±0.01 2.99±0.02 358.1±1.9 0.48±0.01 99.52±0.39 98.23±0.30 
F6 8.27±0.06 2.93±0.10 360.8±2.2 0.51±0.02 100.66±0.4 98.80±0.50 
F7 8.29±0.08 2.99±0.13 361.5±3.4 0.61±0.03 97.30±0.05 97.76±0.89 
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8.12 IN-VITRO RELEASE PROFILES OF THE FORMULATIONS 
Table No.39 In-vitro release profiles of Omeprazole formulations F1 to F6 
S.No 
Time 
(min) 
Cumulative % of drug release 
F1 F2 F3 F4 F5 F6 
1 0 0 0 0 0 0 0 
2 120 18.65 16.75 11.95 7.54 10.67 6.21 
3 130 47.18 41.69 40.65 37.58 44.72 39.05 
4 140 59.84 58.21 51.95 49.95 56.02 54.10 
5 150 74.36 69.54 66.36 63.84 69.20 64.62 
6 165 89.23 83.70 78.65 72.25 84.74 79.65 
7 180 97.65 99.58 98.62 92.98 97.50 98.68 
8 195 _ _ _ 101.36 _ _ 
 
Drug release criteria according to USP 
No individual value should exceed 10% when dissolved in the acidic phase 
after 2hrs of operation and not less than 75% should be released in buffer solution 
after continuous operation of the apparatus for 45min. 
Omeprazole granules are coated with cellulose and methacrylic enteric coating 
polymers and are studied for their capacity to withstand the compression force during 
compression into a tablet form.  
Formulations which obey the above specifications are generally treated as the best 
formulations. 
In formulations F1, the Omeprazole granules are coated with 6% HPMC P 
enteric coating and plasticized with 2% PEG. Even the drug release in 45min is more 
than 75% , it does  not met the specification in acid phase. Increase in enteric coating 
to 8% in F2 formulation does not met the specifications in acid phase. 
This is because of weak mechanical properties of Cellulose mechanical 
properties and rupture of coating layer during compression. 
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Further trials were conducted with methacrylic polymers such as Eutragit and 
Kollicoat. 
Formulation F3 and F4 are coated with increasing Kollicoat enteric coating 
polymer (6 and 8%) and plasticizer (2%). An F3 formulation does not met the 
recommendations in Acid phase but acceptable drug release in acid phase when 
compared to cellulose polymers. Still increase in enteric and plasticizer ratios in F4 
formulation met the recommendations of USP in Acid phase and but not in  Buffer 
phase. 
Further trials are done with Eutragit polymer for finding out the best 
formulation to the above specifications. Formulations F5 and F6 are coated with 
Eutragit and plasticized with PEG. 
Formulation F5 does not met the acid phase specifications, but F6  met the 
USP specifications of both in Acid phase and buffer phase. 
None of the formulations other than F6 passed the above criteria and hence is 
selected as the best formulation .Hence the above formulation has been optimized and 
has been further proceeded to the stability studies. 
 
Graph No.3 Comparitive Invitro drug  release data for Omeprazole F1&F2 formulations 
0
10
20
30
40
50
60
70
80
90
100
110
0 15 30 45 60 75 90 105 120 135 150 165 180 195 210
F1 F2Time(min)
C
u
m
u
la
ti
v
e
%
 o
f 
d
ru
g
 R
el
e
a
se
Chapter-8                                                                                   Results and Discussion 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode                   98 
 
Graph No.4 Comparitive Invitro release data for Omeprazole F3 & F4 formulations 
 
 
 
 Graph No.5 Comparitive Invitro release data for Omeprazole F5 & F6 formulations 
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Table No.40 In-vitro release profiles of Domperidone formulations F1 to F7 
S.No 
Time 
(hrs) 
Cumulative % of drug release 
F1 F2 F3 F4 F5 F6 F7 
1 0 0 0 0 0 0 0 0 
2 0.5 10.36 8.69 7.32 5.02 7.68 7.30 12.06 
3 1.0 18.35 15.06 12.06 10.32 14.36 15.40 20.22 
5 2 33.54 31.85 24.65 20.76 30.36 27.26 38.39 
7 4 53.98 49.96 36.25 32.02 46.96 41.32 58.32 
9 6 73.12 67.32 49.36 46.62 61.36 53.06 70.65 
11 8 90.37 83.69 64.25 59.68 77.36 65.32 81.36 
13 10 98.74 98.21 78.02 73.98 92.39 76.12 91.46 
14 11 _ 99.36 84.12 80.36 98.93 82.69 96.56 
15 12 _ _ 90.68 85.02 _ 87.36 98.95 
Different viscosity grades of the polymer like K4M and K15M at different 
concentrations have been done to study their effect on the release profile of 
Domperidone. 
According to the USP, the amount of Domperidone release at different time 
points is given below 
 Table No.41 Drug release criteria according to USP 
S. No Time (hours) Amount released 
1. 1 Between 10% and 30% 
2. 2 Between 30% and 55% 
3. 4 Between 55% and 80% 
4. 8 Not less than 80% 
 
Formulations which obey the above specifications are generally treated as the 
best formulations. 
Chapter-8                                                                                   Results and Discussion 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode                   100 
Three different concentrations of HPMC K4M are subjected to the drug 
release studies for formulations F1 and F2 
F1 formulation at HPMCK4M concentration of 20% releases about 98% of the 
drug in 10hrs when compared with the other formulations i.e, F2  at concentrations of 
30%  which releases 99%  in 11 hrs  
Further trials were conducted with HPMC of grade K15M to observe the 
release characteristics at the same concentrations to the formulations F3 and F4. 
Similar trials are conducted with the grade K15M and all the above 
formulations failed to meet the USP criteria of drug release. Increasing the 
concentration of the polymer in the above cases also retarded the drug from getting 
released 
Further trials have been conducted with combination of HPMC K4M and 
K15M to study its effect on the release of the drug. 
Formulations F5-F7 are formulated by the combination of HPMC K4M and 
K15M. On increasing the HPMC K15M the drug release was retarded. At polymer 
concentration of 10% of HPMC K4M and 20% of HPMC K15M proved to be 
effective in meeting the USP criteria of drug release. 
 According to the USP the drug release for Domperidone by the end of the 
eighth hour should not be less than 80% and the entire drug should be released within 
the 12 hours. 
None of the formulations other than F7 passed the above criteria and hence is 
selected as the best formulation .Hence the above formulation has been optimized and 
has been further preceded to the stability studies. 
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Graph No.6 Comparitive Invitro release data for Domperidone F1 & F2 formulations 
 
Graph No.7 Comparitive Invitro release data for Domperidone F3 & F4 formulations 
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 Graph No.8 Comparative Invitro release data for Domperidone F5, F6 & F7 
formulations 
8.13 RELEASE KINETICS 
Table No.42 Kinetics of release data of different Domperidone batches 
S.No 
Batch 
No 
Zero 
order 
First 
order 
Higuchi 
Korsmeyer Peppas Hixson 
crowell R
2
 n 
1 F1 0.976 0.887 0.995 0.953 0.744 0.975 
2 F2 0.978 0.839 0.996 0.947 0.749 0.955 
3 F3 0.993 0.932 0.981 0.965 0.768 0.975 
4 F4 0.996 0.956 0.980 0.951 0.823 0.983 
5 F5 0.985 0.798 0.993 0.931 0.763 0.942 
6 F6 0.976 0.967 0.995 0.929 0.670 0.989 
7 F7 0.935 0.894 0.995 0.931 0.605 0.983 
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All the formulations are tested for their release properties. The kinetics of all 
the formulations is illustrated above. 
  F1, F2, F5, F6 and F7 follow Higuchi kinetics whereas F3 and F4 of the 
formulations followed zero order. 
All formulations show n value greater than 0.45 and less than 0.89 indicating 
that the drug release follows follows Non-Fickian transport.  
 
  
 
 
 
 
 
 
 Graph No.9  Zero order kinetics for Domperidone Optimized Formulation 
 
         
  
 
 
 
 
 Graph No.10  First order kinetics for Domperidone Optimized Formulation 
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 Graph No.11 Higuchi Model for Domperidone Optimized Formulation 
    
 Graph No.12   Korsmeyer-peppas Model for Domperidone Optimized Formulation 
       
 
  Graph No.13 Hixson crowell Kinetcs plot for Domperidone Optimized Formulation 
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 8.14 Comparison of the Best formulation with Marketed product 
 Table No.43 Comparison of the in-vitro release profiles of Omeprazole F7 and marketed 
product 
S.No Time(min) Marketed F7 
1 120 5.26 6.21 
2 130 36.95 39.05 
3 140 51.25 54.10 
4 150 66.02 64.62 
5 165 79.25 79.65 
6 180 99.95 98.68 
 
 
Graph No.14 Comparison of the In-vitro release profiles of Omeprazole F7 and marketed 
product 
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Table No.44 Comparison of the in-vitro release profiles of Domperidone F7 and 
marketed product 
S.No Time(hrs) Marketed F7 
1 1 15.91 20.22 
2 2 31.96 38.39 
3 4 55.02 58.32 
4 8 81.05 81.36 
5 12 97.68 98.95 
 
 
 
  Graph No.15 Comparitive In-vitro release profiles of Domperidone F7 and marketed 
product 
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 8.15 Similarity factor and difference factor assessment 
          Table No.45 Similarity factor and difference factor assessment 
S.No Formulations 
Omeprazole Domperidone 
F1 factor F2 factor F1 factor F2 factor 
1 F1 18.79 45.93 17.97 21.23 
2 F2 14.24 51.17 11.61 28.56 
3 F3 9.09 59.88 20.80 43.12 
4 F4 12.70 53.95 26.93 38.07 
5 F5 13.29 52.95 17.04 28.41 
6 F6 1.07 85.31 18.01 45.58 
7 F7 1.07 85.31 4.06 71.73 
 
The range for all the Omeprazole formulations for Difference factor 1.07 to 
18.79 and the range for similarity factor is 45.93 to 85.31 .Difference factor of 1.07 
and similarity factor of 85.31 of the optimized formulation, F7 corresponds to 
marketed products infering that the in-vitro dissolution profile is matching the latter. 
The range for all the Domperidone formulations for Difference factor 4.06 to 
28.05 and the range for similarity factor is 21.23 to 71.73 .Difference factor of 4.06 
and similarity factor of 71.73 of the optimized formulation, F7 corresponds to 
marketed products infering that the in-vitro dissolution profile is matching the latter. 
The release profile is found to be more or less similar with the marketed 
product. 
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8.16 STABILITY STUDIES 
The formulation is stored at Accelerated conditions like 40°C and 75% RH for 
a period of three months. For stability study, the tablets were sealed in HDPE 
containers. Sampling is done every month and the tablets are tested for any liable 
changes in the hardness, friability, drug content and in-vitro dissolution. 
Table No.46 Characteristics of the tablets during stability studies 
Evaluation 
Parameters 
Storage condition   40
˚
C / 75 % RH 
 Initial 1
st
 month 2
nd
 month 3
rd 
month 
Description 
White and           
red color  
round shape 
complies complies complies 
Hardness (kg/cm
2
) 8.4±0.4 8.3±1.2 8.3±0.6 8.3±0.8 
Thickness (mm) 3.04±0.01 3.02±0.02 2.93±0.01 3.03±0.03 
Weight 
Variation(mg) 
362.4±0.45 360.2±0.12 361.3±0.07 360.2±0.13 
Friability (%) 0.654 0.554 0.754 0.654 
Assay(%)       
Omeprazole Layer 
Domperidone Layer 
 
99.24±0.11%    
98.68±0.08% 
 
98.56±0.05% 
98.15±0.12% 
 
97.86±0.06% 
98.26±0.16% 
 
97.26±0.14%  
97.54±0.08% 
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Table No.47  Drug release of the Omeprazole optimised formulation during stability 
studies 
 
 
 
 
        Graph No.16 Drug release of the Omeprazole optimised formulation during 
stability studies 
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Table No.48 Drug release of the Domperidone optimised formulation during stability 
studies 
 
            Graph No.17  Drug release of the Domperidone optimized formulation during 
stability studies 
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9. SUMMARY AND CONCLUSION 
SUMMARY 
In the present study an attempt has been made to Formulate and evaluate the 
multiparticulate delayed release Omeprazole as one layer and sustained release 
Domperidone as another layer. 
Omeprazole is a PPI which is mainly used in the treatment of GERD. During 
GERD, the LES(lower esophagus sphinter) pressure tone decreases and causes 
backflow of acid from stomach to esophagus causing heartburn and possible injury to 
the esophagus. So, to increase the LES pressure Domperidone is given along with 
Omeprazole which acts as anti-emetic and increases the LES pressure and prevents 
efflux of stomach contents. 
Omeprazole has long time binging affinity to the parietal H+/K+ ATPase 
enzyme. As the drug is instable in acidic pH, it is formulated as delayed release form. 
Domperidone has half life of 7hrs and hence it is formulated in SR form.thus the 
therapeutic concentrations of both drugs can be maintained for longer period of time 
i.e., up to 24hrs. Thus one daily dose of Omeprazole and Domperidone bilayer tablet 
was formulated and evaluated. 
In the formulation of Bilayer tablet, Omeprazole compressible enteric coated 
granules were prepared by using different enteric coated polymers such as HPMC 
Phthalate,Eudragit NE30D and Kollicoat MAE30DP  with different ratios and 
plastisized with PEG. Two different grades of  HPMC polymer are used to study the 
release of Domperidone. 
The prepared tablets were evaluated for hardness, weight variation, friability, 
drug content uniformity and in-vitro dissolution studies.F7 formulation showed good 
evaluation and drug release studies. The dissolution profiles of all the formulations 
are compares with innovator by calculating the f2 values. F7 has obtained the highest 
f2 value, hence F7 is considered to be the optimised formulation. Stability studies 
were carried out for F7 formulation and the values were with in the permissible limits.  
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CONCLUSION 
In this present study nine formulations of enteric coated Omeprazole granules 
and Domperidone are formulated into a bilayer tablet. 
The Omeprazole compressible enteric coated granules were prepared by using 
different enteric coated polymers such as HPMC Phthalate, Eutragit NE30D and 
Kollicoat MAE30DP with different ratios and plasticized with PEG. The Omeprazole 
granules which are coated with 8% Eutragit and plasticized with 2%PEG meet the 
USP criteria in drug release. From the above data it is evident that the formulation F7 
shows satisfactory drug release both on acid phase and buffer phase and complies 
with all the pharmacopoeial limits before and after the stability studies and is the most 
suitable composition for the delayed release of Omeprazole. 
Two different grades of HPMC polymer are used to study the release retarding 
activity. Different concentrations of polymer are used in the sustained release layer 
and their effect on the release of Domperidone is explored. The formulation F7 is 
found to be the best formulation since it meets the USP criteria in the drug release. 
HPMC of grade K4M and K15M at a concentration of 20% and 10% releases the drug 
as per the USP specifications. The cumulative drug release at the end of twelfth hour 
is 100%.From the above data it is evident that the formulation F7 shows satisfactory 
sustained release and complies with all the pharmacopoeial limits before and after the 
stability studies and is the most suitable composition for the sustained release of 
Domperidone. 
Finally I conclude that F7 formulation shows the best release in both the layers 
(Omeprazole and Domperidone) and that may fulfils the objective of the study. 
The stability studies were performed according to in-house specifications for 
the optimized formulation. The tablets were kept at accelerated condition (40±2
º 
C/ 
75±5% RH) for a period of three months. The obtained results were within the 
specifications. 
 
Chapter 10       
 
 
 
 
 
 
   REFERENCES 
Chapter-10                                                                                                     References 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  113 
10.REFERENCES 
1. Ding X, Alani AWG, Robinson JR. Extended release and targeted drug delivery 
systems. In : The Science and Practice of Pharmacy. 2005; (Remington, Ed.), Twenty 
first edition, volume 1, pp. 939-964 ; Lippincott Williams and Wilkins. 
2. Karande A.D., Dhoke S.V., Yeole P.G. Formulation and evaluation of bilayer tablets 
with antihypertensive drugs having different release patterns. Indian Drugs, 2006; 
43(1): 44-50. 
3. R.Nagaraju and Rajesh Kaza. Formulation and evaluation of bilayer sustained release 
tablets of Salbutamol and Theophylline. International Journal of Pharmaceutical 
Sciences and Nanotechnology, 2009; 2(3): 638-646. 
4. Shailesh kumar, Venkata Bala Krishna Rao, N.Kannapan, Amitsankar Dutta. 
Formulation and evaluation of Atorvastatin calcium and Nicotinic acid in a bilayer 
tablets. Journal of Pharmacy Research, 2009; 2(7): 1256-1258. 
5. Pharmaceutics, The science of dosage form design, Aulton M.E, 2nd edition, 1998, 1, 
289-306, 412. 
6. Modern Pharmaceutics, Gilbert S.Banker Christopher T.Rhodes, 4th edition, 2006, 
121, 501-514. 
7. The Theory and practice of Industrial Pharmacy, Leon Lachamnn., Herbert 
A.Liebermann., Joseph L.Kanig, 2
nd 
edition, 2003,1, 330-331. 
8. Martino Fusca, Dagmer Farber, Heppinheim, Patented on Multilayer tablets, 2001 
Patent No. US 6,254,886 B1 
9. Sachin S. Kale, Viraj S. Saste, Prajkta L. Ughade, Dheeraj T. Baviskar. Review article 
on Bilayer Tablets. International Journal of Pharmaceutical Sciences Review and 
Research.2011, Volume 9, Issue 1: 25-30 
10. Jitendra R. Amrutkar, Mohan G.Kalaskar,Varsha G.Shrivastav, P.G.Yeole. Bilayer 
tablets of Metformin hydrochloride and Glilclazide. A Novel approach in treatment of 
diabetes, international Jour of Pharm Research and Development,2009; 1(2). 
11. Wen H, Park K. Fluid bed coating and granulation for CR delivery In : Oral 
controlled release formulation design and drug delivery: theory to practice. 2010:. 
115-121 ; John Wiley and Sons. 
Chapter-10                                                                                                     References 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  114 
12. Brahmankar DM, Jaiswal BS. Controlled release medication. In: Biopharmaceutics 
and Pharmacokinetics a treatise. 1995: pp. 335-371, Vallabh Prakashan 
13. Sansom LN. Oral extended release products. Aust Prescr. 1999 ; 22: 88-90. 
14. Richards JH. Role of polymer permeability in the control of drug release. In: Polymer 
permeability. 1985; ( Comyn J, Ed.,), pp : 220-256; Springer 
15. Chinam Niranjan Patra, Arethi Bharani Kumar, Hemat Kumar Pandit, Satya Prakash 
singh, Meduri vimala devi. Design and evaluation of Sustained Release Bilayer 
tablets of propronalol hydrochloride. Acta Pharm; 2007; 57: 479-489. 
16. Physical Pharmacy, Martin’s, P.S Patrick J. 5th edition, 2006, 1, 337-354, 553-558. 
17. Ding X, Alani AWG, Robinson JR. Extended release and targeted drug delivery 
systems. In : The Science and Practice of Pharmacy. 2005; (Remington, Ed.), Twenty 
first edition, volume 1, pp. 939-964 ; Lippincott Williams and Wilkins. 
18. Rane M, Parmar J, Rajabi-Siahboomi. Hydrophilic matrices for oral extended release: 
influence of fillers on drug release from HPMC matrices. Pharma Times. 2010 ; 42: 
41-45. 
19. Brahmankar DM, Jaiswal BS. Controlled release medication. In: Biopharmaceutics 
and Pharmacokinetics a treatise. 1995: pp. 335-371, Vallabh Prakashan. 
20. Qiu Y. Rational design of Oral modified release drug delivery systems. In: 
Developing solid oral dosage forms Pharmaceutical theory and practice. 2009; (Qiu, 
Y , Chen, Y,and Zhang, GZ,Eds.,),  pp. 469-499, Elsevier. 
21. Sanjahan Abdul, Anil V. Chandewar, Sunil B. Jaiswal, A flexible technology for 
Modified-Release drugs, J. Of Controlled release, 147 (2010) 2-16. 
22. V.S.N. Murthy, and J.Vijaya Ratna, Key formulation variables in Tabletting of 
Coated Pellets, Indian J.of Pharmaceutical Sciences, 2008, pp.555-564 
23. Ann Debunne, Chris Vervaet, Debby Mangelings, Jean-Paul Remon, Compaction of 
enteric-coated pellets: influence of of formulation and process parameters on tablet 
properties and invivo evaluation, European J. Of Pharmaceutical sciences, 22(2004): 
305-314. 
24. A.Dashevsky, K.Kolter, R.Bodmeier,Compression of pellets coated with various 
aqueous polymer dispersions, International J.of Pharmaceutics 279(2004): 19-26 
25. G.Sailesh, T.E.G.K.Murthy, Pavan kumar sm, Compression of coated 
Multiparticulates from Pharmainfo.net. 
Chapter-10                                                                                                     References 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  115 
26. Mangesh E. Bhad, Shajahan Abdul, Sunil B. Jaiswal, Anil V. Chandewar, Jayesh M. 
Jain, Dinesh M. Sakarkar, MUPS Tablets-A brief Review, International Journal of 
PharmTech Research, 2010 Vol.2 :pp 847-855 
27. Vogeleer J. Bilayer tablets-why special technology is required. Powder 
pharmaceutical technology division. Niro pharma systems  
28. Mehul P. Challenges in the formulation of bilayered tablets. International journal of 
Pharma.Research and Development. 2010 ; 2: 30-42. 
29. Patel Mehul, Ganesh Nanjan, Kavitha, Tamizh Mani, Challenges in the formulation of 
Bilayer tablets:A review, International J. Of Pharma. Research and Development, 
2005: pp 30-42. 
30. www.nih.gov/medlineplus/druginfo/meds/a 693050.html. 
31. www.medicinenet.com/gerd/page6.html 
32. NIH Publication No 0-0882 June 2003 
33. PDSP Ki Database(http//pdsp.med.unc.edu/pdsp.php) 
34. http:/ / www. drugbank. ca/ cgi-bin/ show_drug. cgi?CARD=APRD00446 
35. http:/ / www. nlm. nih. gov/ cgi/ mesh/ 2009/ MB_cgi?term=57808-66-9& rn=1 
36. http:/ / www. drugbank. ca/ cgi-bin/ show_drug. cgi?CARD=APRD00418 
37. Swann IL, Thompson EN, Qureshi K (November 1979). "Domperidone or 
metoclopramide in preventing  chemotherapeutically inducednausea and vomiting" 
British medical journal 2 (6199): 1188. 
38. Journal of Pediatrics 2008 (http:/ / www. ncbi. nlm. nih. gov/ pubmed/ 
18589449?dopt=Abstract) 
39. Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian 
Medicines Handbook; 2006. 
40. http://eudragit.evonik.com/product/eudragit/en/products-services/eudragit-
products/sustained-release-formulations/ne-30-d/pages/default.aspx 
41. Volker Buhler, Functional polymers for pharmaceutical Insustry, BASF, 2007 pp 69-
97 
42. Raymond C Rowe, Paul J Sheskey,Sian C Owen Hand book of Pharmaceutical 
excipients Fifth edition. 
43. Stedman CA, Barclay ML (August 2000). "Review article: comparison of the                                                                                                                                                                                                                                                                                                                                                                                                                                             
pharmacokinetics, acid suppression and efficacy of proton pump inhibitors". Aliment 
Pharmacol Ther 14 (8): 963–78 
Chapter-10                                                                                                     References 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  116 
44. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition,                       
Biomedical   publications, Foster City, CA, 2008: 1146-1147 
45. Collett J, Moreton C.  Modified release peroral dosage forms. In: Pharmaceutics: The     
science of dosage form design. 2002; (Aulton, ME.,Ed.) Second edition:pp. 289-305,  
Churchill Livingstone. 
46. Duphar BV, Weesp. Design for drug excipient interaction studies. Drug development 
and Industrial pharmacy. 1983; 9 : 43-55. 
47. Meyers RA. Interpretation of IR spectra, a practical approach. Encyclopedia of 
analytical chemistry. 2000 : 10815 – 10837. 
48. Indian pharmacopeia volume-2 2007 
49. Huanjo kim.reza fassihi. Pharma Resea,vol.14(10).1997 :1415-1421 
50. Mamajek RC, Moyer ES. Drug dispensing device and method. US Patent 4 207 890. 
June 17, 1980. 
51. Rakesh patil, ashok bariaijps vol.1 issue 2, 2009 31-32. 
52. Leon Lachman et.al; The Theory and Practice of Industrial Pharmacy, 3rd edition, 
Page. No: 293- 345 
53. Leon Shargel, Susanna Pong, Andrew B.C., Applied Biopharmaceutics and 
Pharmacokinetics, Modified-Release Drug Products, Pg 515 Fifth Edition, 2004 
54. Chapter 905, Uniformity of Dosage Units and Chapter 1151, Pharmaceutical Dosage 
Forms, United States Pharmacopoeia, 2008 
55. V. Jannin, E.Pochard and O. Chambin, Influence of poloxamers on the dissolution 
performance and stability of controlled-release formulations containing Precirol ATO 
5, PubMed, 2005 
56. FDA guidance on “Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms 
57. Korsmeyer RW, Gurny R, Doelker E, Buri P. Peppas NA. Mechanisms of solute 
release from porous hydrophilic polymers. Int J Pharm. 1983 
58. Chien Y.W., Controlled- and modulated-release drug-delivery systems. Encyclopedia 
of pharmaceutical technology. New York, Dekker, pgs 281-313, 1992. 
59. FDA guidance on “Dissolution Testing of Immediate Release Solid Oral Dosage 
Forms”. 
60. Acetazolamide, USP Monograph and Acetazolamide Tablets, USP Monograph, 
United States Pharmacopoeia, 2008 
Chapter-10                                                                                                     References 
 
Department of Pharmaceutics, The Erode College of Pharmacy and Research Institute, Erode  117 
61. Korsmeyer RW, Gurny R, Doelker E, Buri P. Peppas NA. Mechanisms of solute 
release from porous hydrophilic polymers. Int J Pharm. 1983 
62. F. S´anchez Rojas., Analytical methodologies for the determination of omeprazole: 
An overview Journal of Pharmaceutical and Biomedical Analysis 44 (2007) :831–844 
63. Bhavesh Patela; Madhabhai Patel., Simultaneous Determination of Omeprazole and 
Domperidone in Capsules by RP-HPLC and Densitometric HPTLC Journal of Liquid 
Chromatography & Related Technologiesw, 30: 1749–1762, 2007 
64. Ajit Kulkarni and Manish Bhatia “Development and evaluation of regioselective 
bilayer floating tablets of Atenolol and Lovastatin for biphasic release profile” Iranian 
Journal of Pharmaceutical Research. 2009; 8 (1): 15-25. 
65. Chien Y.W., Controlled- and modulated-release drug-delivery systems. Encyclopedia 
of pharmaceutical technology. New York, Dekker : 281-313, 1992. 
66. Jung AD. Gastroesophageal reflux in infants and children. 
 
